

RECEIVED  
STIC  
BIOTECH / CHEMICAL

## ONLINE SEARCH REQUEST FORM

\*\*\*\*\*  
USER

Minneapolis 5:13

SERIAL NUMBER

8/335296

ART. UNIT

1813

PHONE

5.3394

DATE

3-20-95

Please give a detailed statement of requirements. Describe as specifically as possible the subject matter to be searched. Define any terms that may have special meaning. Give examples or relevant citations, authors, or keywords, if known.

You may include a copy of the broadest and or relevant claim(s).

Janet K. Yamamoto

Please search author/inventor Nils D. Pedersen

Please search:

- Vaccine against FIV  
(feline immunodeficiency virus)

adjuvant

method of protecting cat against  
FIV infection

immunogen capable of eliciting  
an immune response protective  
against FIV infection

File date → 8/26/87

Thanks

Minneapolis

\*\*\*\*\*  
STAFF USE ONLY

COMPLETED

SEARCHER

ONLINE TIME

(in minutes)

NO. OF DATABASES

TOTAL TIME

3/21  
May 4218

27

=> fil ca

FILE 'CA' ENTERED AT 11:18:38 ON 21 MAR 95  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 1995 AMERICAN CHEMICAL SOCIETY (ACS)

Minnifield  
335296

FILE COVERS 1967 - 18 Mar 1995 (950318/ED) VOL 122 ISS 12

To help control your online searching costs, consider using the  
HCA File when using the FSEARCH command or when conducting  
SmartSELECT searches with large numbers of terms.

CAPLUS IS NOW ONLINE!

=> s (fiv or feline immunodeficien? virus)(5a)adjuvant

191 FIV

2811 FELINE

16235 IMMUNODEFICIEN?

149035 VIRUS

170 FELINE IMMUNODEFICIEN? VIRUS

(FELINE(W) IMMUNODEFICIEN?(W)VIRUS)

11365 ADJUVANT

L1 0 (FIV OR FELINE IMMUNODEFICIEN? VIRUS) (5A)ADJUVANT

=> s (fiv or feline immunodeficien? virus)

191 FIV

2811 FELINE

16235 IMMUNODEFICIEN?

149035 VIRUS

170 FELINE IMMUNODEFICIEN? VIRUS

(FELINE(W) IMMUNODEFICIEN?(W)VIRUS)

L2 228 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

=> s 12 and vaccin?

19549 VACCIN?

L3 29 L2 AND VACCIN?

=> d 1-29 an .mh;s immunogen and immune response and 12

L3 ANSWER 1 OF 29 CA COPYRIGHT 1995 ACS

AN 122:7950 CA

TI Antigenic peptides capable of inducing neutralizing antibodies against feline immuno-deficiency virus

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

IN Keldermans, Cornelia Elisabeth Johanna Maria; Horzinek, Marian Christian; De Ronde, Anthony; Egberink, Hermanus Franciscus

PI WO 9420622 A1 940915

AI WO 94-EP812 940310

PY 1994

AB Polypeptides of the feline immuno-deficiency virus surface protein, capable of inducing neutralizing antibodies against **FIV** are described for use in **vaccines**. A neutralizing monoclonal antibody recognizing such a peptide of the **FIV** surface protein is also described. The gene for the surface protein was cloned by screening a gene bank from **FIV**-113-infected cells with probes from the long terminal repeat and the pol gene that flank the surface protein gene. Peptides of the protein were manufd. as fusion proteins with the galK gene product in Escherichia coli and tested for their ability to induce an immune response in cats.

L3 ANSWER 2 OF 29 CA COPYRIGHT 1995 ACS

AN 121:212888 CA

TI Encapsulation of DDCTP in feline erythrocytes and inhibition of **FIV** infection

SO Adv. Biosci. (Oxford) (1994), 92(Carrier and Bioreactor Red Blood Cells for Drug Delivery and Targeting), 59-66

CODEN: AVBIB9; ISSN: 0065-3446

AU Fraternale, A.; Rossi, L.; Silvotti, L.; Piedimonte, G.; Magnani, M.

PY 1994

AB Since **FIV** infection is considered a useful animal model for studying AIDS antiviral therapy and **vaccine** development, cat erythrocytes were loaded with dideoxycytidine-5'-triphosphate (DDCTP) using a procedure of encapsulation based on hypotonic dialysis, isotonic resealing and reannealing. The dialysis method used for other mammalian erythrocytes was modified

specifically for cat red blood cells (RBCs) because of their biochem. characteristics which make them very fragile. Several conditions were tested to optimize DDCTP encapsulation into cat erythrocytes; changes were made in the osmolarity of dialyzing buffer and dialysis time. The procedure developed allowed the encapsulation of about 0.6  $\mu$ moles DDCTP/mL RBC with a 70% cell recovery. Cat DDCTP-loaded RBCs were able to reduce FIV prodn. by infected macrophages. The method developed will be useful in studying other drugs in cats.

L3 ANSWER 3 OF 29 CA COPYRIGHT 1995 ACS

AN 121:203101 CA

TI Induction of **feline immunodeficiency**

**virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide**

SO J. Virol. (1994), 68(9), 5835-44

CODEN: JOVIAM; ISSN: 0022-538X

AU Flynn, J. N.; Cannon, C. A.; Beatty, J. A.; Mackett, M.; Rigby, M. A.; Neil, J. C.; Jarrett, O.

PY 1994

AB The role of cellular immunity in the establishment and progression of immunosuppressive lentivirus infection remains equivocal. To develop a model system with which these aspects of the host immune response can be studied exptl., the authors examd. the responses of cats to a hybrid peptide contg. predicted T- and B-cell epitopes from the gag and env genes of **feline**

**immunodeficiency virus (FIV)**. Cats were

immunized with an unmodified 17-residue peptide incorporating residues 196 to 208 (from gag capsid protein p24) and 395 to 398 (from env glycoprotein gp120) of the FIV Glasgow-8 strain by using Quil A as an adjuvant. Virus-specific lymphocytotoxicity was measured by chromium-51 release assays. The target cells were autologous or allogeneic skin fibroblasts either infected with recombinant FIV gag **vaccinia** virus or pulsed with FIV peptides. Effector cells were either fresh

peripheral blood mononuclear cells or T-cell lines stimulated with FIV peptides in vitro. Cytotoxic effector cells from immunized cats lysed autologous, but not allogeneic, target cells when they were either infected with recombinant FIV gag

**vaccinia** virus or pulsed with synthetic peptides comprising residues 196 to 205 or 200 to 208 plus 395. Depletion of CD8+ T cells, but not CD4+ T cells, from the effector cell population abrogated the lymphocytotoxicity. Immunized cats developed an antibody response to the 17-residue peptide immunogen and to recombinant p24. However, no antibodies which recognized smaller constituent peptides could be detected. This response correlated with peptide-induced T-cell proliferation in vitro. Thus, cytotoxic T lymphocytes specific for FIV can be induced following immunization with an unmodified short synthetic peptide.

L3 ANSWER 4 OF 29 CA COPYRIGHT 1995 ACS

AN 121:117446 CA

TI Removal of the cleavage site of recombinant **feline**

**immunodeficiency virus** envelope protein

facilitates incorporation of the surface glycoprotein in immune-stimulating complexes

SO J. Gen. Virol. (1994), 75(8), 2097-102

CODEN: JGVIA Y; ISSN: 0022-1317

AU Rimmelzwaan, Guus F.; Siebelink, Kees H. J.; Huisman, Robin C.;  
Moss, Bernard; Francis, Michael J.; Osterhaus, Albert D. M. E.  
PY 1994

AB Recombinant **vaccinia** viruses were constructed that expressed the complete env gene of **feline immunodeficiency virus** with or without the nucleotide sequence encoding the cleavage site between the surface (SU) protein and the transmembrane (TM) protein. The removal of this cleavage site resulted in the expression of a 150 K protein that was processed into a 130 K protein and was not cleaved into the SU and the TM proteins. Removal of the cleavage site also facilitated incorporation of the SU protein in immune-stimulating complexes (iscoms). Antibody responses to both an SU and a TM peptide representing two immunodominant B cell epitopes were measured. These were higher in cats immunized with iscoms prep. from the cleavage site-deleted envelope protein than in cats immunized with iscoms prep. from the native envelope protein or immunized with the envelope protein and the adjuvant Quil A.

L3 ANSWER 5 OF 29 CA COPYRIGHT 1995 ACS

AN 121:33142 CA

TI Anti-feline immunodeficiency virus (**FIV**) vaccines

SO PCT Int. Appl., 68 pp.  
CODEN: PIXXD2

IN Francis, Michael James

PI WO 9406471 A1 940331

AI WO 93-GB1974 930920

PY 1994

AB A synthetic polypeptide comprising part or all of the antigenic fragment of the protein encoded by **FIV** env gene is provided to be used as a **vaccine** or diagnostics. Nucleic acids encoding the polypeptide, methods for recombination prep. of the polypeptide, and their use in combating and diagnosing **FIV** infection are also described.

L3 ANSWER 6 OF 29 CA COPYRIGHT 1995 ACS

AN 120:321354 CA

TI Epitopes of feline immunodeficiency virus (**FIV**) gene env protein and anti-**FIV** vaccines

SO PCT Int. Appl., 49 pp.  
CODEN: PIXXD2

IN Osterhaus, Albertus Dominicus Marcellinus Erasmus; Siebelink, Cornelus Herman Johannus

PI WO 9402612 A1 940203

AI WO 93-EP1860 930715

PY 1994

AB The present invention provides nucleic acids corresponding to or related to **FIV** gene env protein residues 483 to 567, their use in the prep. of **vaccines** against **FIV**, and synthetic polypeptides encoded by them. The gene env protein region described above was identified as a neutralization site by generating escape mutants in the env gene. This region, located in hypervariable regions V4 and V5, may serve as a basis for a **vaccine** against **FIV** infection in cats (no data).

L3 ANSWER 7 OF 29 CA COPYRIGHT 1995 ACS

AN 120:317337 CA

TI Recombinant retroviral vector against feline leukemia virus (FeLV) and/or **feline immunodeficiency virus (FIV)**

SO PCT Int. Appl., 50 pp.

CODEN: PIXXD2

IN Lee, William T. L.; Serbin, John J.; Jolly, Douglas J.; Barber, Jack R.; Chada, Sunil; Chang, Stephen M. W.

PI WO 9406921 A1 940331

AI WO 93-US9070 930921

PY 1994

AB A method for treating or preventing FeLV infections by administering a feline vector construct which directs the expression of .gtoreq.1 immunogenic portions of a FeLV antigen to elicit a cellular immune response is disclosed. Also provided are methods and vector constructs for treating or preventing **FIV** infections, either sep. or in combination with the above-described methods for treating or preventing FeLV infections. The antigen may be selected from p15gag, p12gag, p10gag, p27gag, p14pol, p80pol, p46pol, gp70env, and p15env of FeLV, as well as p15gag, p24gag, p10gag, p13pol, p62pol, p15pol, and p36pol of **FIV**. Prepn. of the expression vectors and the immunol. efficacy of the vectors in felines were shown.

L3 ANSWER 8 OF 29 CA COPYRIGHT 1995 ACS

AN 120:296657 CA

TI Proteolytic processing-resistant envelope glycoprotein analog of **feline immunodeficiency virus (FIV)** and anti-**FIV** vaccines

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

IN Osterhaus, Albertus Dominicus Marcelliners Erasmus; Siebelink, Cornelus Herman Johannus; Rimmelzwaan, Gustaaf Frank

PI WO 9402613 A1 940203

AI WO 93-EP1861 930715

PY 1994

AB The present invention provides a synthetic **FIV** polypeptide comprising an amino acid sequence substantially corresponding to all or a portion of the **FIV** envelope protein, or an antigenic fragment or functionally-equiv. variant thereof, in which the proteolytic cleavage site between the transmembrane and surface polypeptides of the native **FIV** envelope precursor protein has been eliminated and which comprises at least a portion of a transmembrane polypeptide and at least a portion of a surface polypeptide. Also provided are nucleic acids encoding such polypeptides, methods for their recombinant expression, **vaccine** compns. contg. them, and their use in combating **FIV**. A recombinant **vaccinia** virus contg. an **FIV** env gene mutated to remove a sequence encoding the cleavage site RRKR was prepd. HeLa cells infected with this virus produced a 150,000 Da protein which was further cleaved to a 130,000 Da protein during over a 24 h period. Immune-stimulating complexes were prepd. from cells infected with the recombinant **vaccinia** virus.

L3 ANSWER 9 OF 29 CA COPYRIGHT 1995 ACS

AN 120:291186 CA  
 TI Identification of three **feline immunodeficiency virus (FIV)** env gene subtypes and comparison of the **FIV** and human immunodeficiency virus type 1 evolutionary patterns  
 SO J. Virol. (1994), 68(4), 2230-8  
 CODEN: JOVIAM; ISSN: 0022-538X  
 AU Sodora, Donald L.; Shpaer, Eugene G.; Kitchell, Barbara E.; Dow, Steven W.; Hoover, Edward A.; Mullins, James I.  
 PY 1994  
 AB **Feline immunodeficiency virus (FIV)** is a lentivirus assocd. with AIDS-like illnesses in cats. As such, **FIV** appears to be a feline analog of human immunodeficiency virus (HIV). A hallmark of HIV infection is the large degree of viral genetic diversity that can develop within an infected individual and the even greater and continually increasing level of diversity among virus isolates from different individuals. The authors' goal in this study was to det. patterns of **FIV** genetic diversity by focusing on a 684-nucleotide region encompassing variable regions V3, V4, and V5 of the **FIV** env gene in order to establish parallels and distinctions between **FIV** and HIV type 1 (HIV-1). The authors' data demonstrate that, like HIV-1, **FIV** can be sepd. into distinct envelope sequence subtypes (three are described here). Similar to that found for HIV-1, the pairwise sequence divergence within an **FIV** subtype ranged from 2.5 to 15.0%, whereas that between subtypes ranged from 17.8 to 26.2%. However, the high no. of synonymous nucleotide changes among **FIV** V3 to V5 env sequences may also include a significant no. of back mutations and suggests that the evolutionary distances among **FIV** subtypes are underestimated. Although only a few subtype B viruses were available for examn., the pattern of diversity between the **FIV** A and B subtypes was found to be significantly distinct; subtype B sequences had proportionally fewer mutations that changed amino acids, compared with silent changes, suggesting a more advanced state of adaptation to the host. No similar distinction was evident for HIV-1 subtypes. The diversity of **FIV** genomes within individual infected cats was found to be as high as 3.7% yet twofold lower than that of **FIV** genomes within individual infected cats was found to be as high as 3.7% yet twofold lower than that within HIV-1-infected people over a comparable region of the env gene. Despite these differences, significant parallels between patterns of **FIV** evolution and HIV-1 evolution exist, indicating that a wide array of potentially divergent virus challenges need to be considered in **FIV** vaccine and pathogenesis studies.

L3 ANSWER 10 OF 29 CA COPYRIGHT 1995 ACS  
 AN 120:268196 CA  
 TI Recombinant feline herpesvirus **vaccine**  
 SO Eur. Pat. Appl., 24 pp.  
 CODEN: EPXXDW  
 IN Willemse, Martha Jacoba; Sondermeijer, Paulus Jacobus Antonius  
 PI EP 576092 A1 931229  
 AI EP 93-201791 930622  
 PY 1993  
 AB The present invention is concerned with a Feline herpesvirus (FHV)

mutant comprising a heterologous gene introduced into an insertion-region of the FHV genome. The invention also relates to a vector **vaccine** comprising such an FHV mutant which expresses a heterologous polypeptide derived from a feline pathogen and induces an adequate immune response in an inoculated host against both FHV and the feline pathogen. An approx. 1-kb open reading frame derived from the FHV genomic DNA digested with SalI was provided for mutation, e.g., by insertion at its BgIII site. Insertion at the BgIII site of the genes for .beta.-galactosidase, the envelope protein of feline leukemia virus, and the envelope protein of **feline immunodeficiency virus**, resp., was also demonstrated. The ability of the mutant FHV to protect cats from clin. signs caused by virulent FHV was shown.

- L3 ANSWER 11 OF 29 CA COPYRIGHT 1995 ACS  
 AN 120:240016 CA  
 TI Gene and protein sequence from the WO isolate of **feline immunodeficiency virus** and their use in diagnosis and prophylaxis of infection  
 SO Eur. Pat. Appl., 56 pp.  
 CODEN: EPXXDW  
 IN Pancino, Gianfranco; Chappey, Colombe; Hurtrel, Bruno; Moraillon, Anne; Klatzmann, David; Sonigo, Pierre; Saurin, William; Avrameas, Alexandre; Strosberg, Arthur Donny  
 PI EP 577458 A1 940105  
 AI EP 93-401538 930616  
 PY 1994  
 AB Nucleotide and protein sequences from **feline immunodeficiency virus** WO are identified and the genes used to manuf. viral peptides for use in diagnostics and prophylaxis, e.g. **vaccines**. Specifically, the env and gag genes and gene products are characterized as are the SU and TM epitopes of the env protein. Sequences were cloned from peripheral blood lymphocytes of infected animals by PCR using primers derived from the corresponding sequences of the Petaluma isolate. These sequences were used to construct full-length copies of the genes. Sequence divergence between the Petaluma and WO isolates were sufficient to differentiate the strains by hybridization. Immunodominant epitopes of the env protein were used in the diagnosis of infection.
- L3 ANSWER 12 OF 29 CA COPYRIGHT 1995 ACS  
 AN 120:86407 CA  
 TI Methods and compositions for **vaccinating against feline immunodeficiency virus**  
 SO U.S., 23 pp. Cont.-in-part of U.S. 5,037,753.  
 CODEN: USXXAM  
 IN Yamamoto, Janet K.; Pedersen, Niels C.  
 PI US 5275813 A 940104  
 AI US 91-739014 910731  
 PY 1994  
 AB The **vaccine** compns. derived from a novel viral isolate designated by **feline immunodeficiency virus (FIV)** include the whole virus, proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compns. are useful in a variety of techniques for detecting and



**vaccinating** against FIV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. **Vaccines** include both wholly and partially inactivated viruses inactivated cell lines expressing FIV antigens, and subunit **vaccines**. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

L3 ANSWER 13 OF 29 CA COPYRIGHT 1995 ACS

AN 119:224280 CA

TI T4 immune stimulating factor (TISF) as immune-enhancing agent for therapeutic use in immunocompromised hosts

SO PCT Int. Appl., 16 pp.

CODEN: PIXXD2

IN Beardsley, Terry R.

PI WO 9317700 A1 930916

AI WO 93-US2056 930309

PY 1993

AB Thymus-derived factor TISF induces or enhances cell-mediated immune responsiveness in mammals. The factor enhances proliferation and differentiation of lymphocytes and other hematopoietic progenitors and enhances the response of animals, esp. mammals, to infectious agents and to malignancies. TISF is useful for treating infection or cancer and as an immunopotentiating adjuvant for coadministration with a **vaccine**. TISF showed beneficial effects in mice infected with influenza virus and in cats infected with **feline immunodeficiency virus**. TISF enhanced antibody responses of dogs to rabies virus when coadministered with killed rabies virus **vaccine**.

L3 ANSWER 14 OF 29 CA COPYRIGHT 1995 ACS

AN 119:224253 CA

TI Induction of protection against viral infection by synergy between viral proteins and viral peptides

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

IN Girard, Marc

PI WO 9308836 A1 930513

AI WO 92-EP2459 921028

PY 1993

AB The immunogenicity of a retroviral envelope glycoprotein is enhanced by addnl. administering .gtoreq.1 peptide derived from a virus-neutralization epitope of the same envelope glycoprotein. The envelope glycoprotein and peptide are administered to induce neutralizing antibodies in the host, e.g. against HIV, simian immunodeficiency virus, HTLV-1, HTLV-2, **feline immunodeficiency virus**, and feline leukemia virus.

Thus, a chimpanzee was immunized first with a series of injections of formalin-inactivated HIV-1 (BRU isolate), then with a series of injections of recombinant **vaccinia** virus whose genome contained a modified gene for HIV-1 glycoprotein gp160env, and finally with 3 injections of neutralization epitope peptide YNTRKSIRIQRGPGRAFVTIGKIGN conjugated through tyrosine (Y) with keyhole limpet hemocyanin. The peptide injections resulted in a marked increase in neutralizing antibody titer and conferred total protection against challenge with HIV-1.

L3 ANSWER 15 OF 29 CA COPYRIGHT 1995 ACS  
 AN 119:87886 CA  
 TI Structure and variations of **feline immunodeficiency virus** envelope glycoproteins  
 SO Virology (1993), 192(2), 659-62  
 CODEN: VIRLAX; ISSN: 0042-6822  
 AU Pancino, Gianfranco; Fossati, Isabelle; Chappey, Colombe; Castelot, Sandrine; Hurtrel, Bruno; Moraillon, Anne; Klatzmann, David; Sonigo, Pierre  
 PY 1993  
 AB The env gene of a **feline immunodeficiency virus** isolate from France (FIV Wo) was characterized. FIV Wo gag and env genes were cloned directly from cat peripheral blood mononuclear cells, using polymerase chain reaction. The env mol. clone was functional and expressed antigenically relevant envelope glycoproteins in vitro. Alignment of FIV Wo sequences with available FIV sequences and application of a regionalization algorithm resulted in delineation of variable and conserved domains of FIV Env. These data were used to build a schematic folding model of FIV envelope glycoproteins. The Env mol. clone, variability map, and structural model constitute helpful tools for future studies of FIV envelope aimed at the detn. of structure-function relationships or design of diagnostics or vaccine reagents.

L3 ANSWER 16 OF 29 CA COPYRIGHT 1995 ACS  
 AN 118:252777 CA  
 TI Animal models in AIDS **vaccine** development, its current status  
 SO Jikken Igaku (1993), 11(5), 640-4  
 CODEN: JIIGEF; ISSN: 0288-5514  
 AU Yamamura, Yasuko; Miyasaka, Masayuki  
 PY 1993  
 AB A review with 25 refs., on the model animals susceptible to human immunodeficiency virus (HIV), with which the effectiveness of **vaccination** is tested. HIV-1 infection occurs in chimpanzee, gibbon ape, and Macaca nemestrina. Infection of HIV-2 or simian immunodeficiency virus (SIV) induces AIDS-like symptoms in Macaca mulatta. Rabbit T cells and macrophages are infected by HIV-1, and the infection efficiency increases upon transfection of human CD4 gene. CD-4 transgenic rabbit are under study. Transient decrease in peripheral CD4+ cells occurs in pathogen-free cat infected with **feline immunodeficiency virus** (FIV). HIV infection to mouse occurs by i.p. administration of HIV-1 infected U937. CD4-transgenic mouse and severe combined immunodeficiency (SCID)-hu mouse are used for HIV infection.

L3 ANSWER 17 OF 29 CA COPYRIGHT 1995 ACS  
 AN 118:232124 CA  
 TI Passive antibody protection of cats against **feline immunodeficiency virus** infection  
 SO J. Virol. (1993), 67(4), 2344-8  
 CODEN: JOVIAM; ISSN: 0022-538X  
 AU Hohdatsu, Tsutomu; Pu, Ruiyu; Torres, Barbara A.; Trujillo, Sherry;

Gardner, Murray B.; Yamamoto, Janet K.

PY 1993

AB All six cats passively immunized with sera from either **feline immunodeficiency virus (FIV)-vaccinated** cats or cats infected with **FIV** (Petaluma strain) were protected from homologous **FIV** infection at a challenge dose that infected all six control cats. Passive immunization with sera from cats **vaccinated** with uninfected allogenic T cells used to grow the **vaccine** virus did not protect either of two cats against the same **FIV** challenge. These results suggest that antiviral humoral immunity, perhaps in synergy with anticellular antibodies, may be responsible for previously reported **vaccine** protection.

L3 ANSWER 18 OF 29 CA COPYRIGHT 1995 ACS

AN 118:232057 CA

TI B epitopes and selection pressures in **feline immunodeficiency virus** envelope glycoproteins

SO J. Virol. (1993), 67(2), 664-72

CODEN: JOVIAM; ISSN: 0022-538X

AU Pancino, Gianfranco; Chappey, Colombe; Saurin, William; Sonigo, Pierre

PY 1993

AB In order to map linear B epitopes in **feline immunodeficiency virus (FIV)** envelope glycoproteins (Env), a random library of **FIV** Env polypeptides fused to .beta.-galactosidase and expressed in *Escherichia coli* was screened by using sera from exptl. **FIV** -infected cats. Five antibody-binding domains in the surface envelope glycoprotein (SU1 to SU5) and 4 in the transmembrane envelope glycoprotein (TM1 to TM4) were mapped. Immunol. anal. with serum samples from naturally or exptl. infected cats of diverse origins revealed a broad group reactivity for epitopes SU2, TM2, and TM3, whereas SU3 appeared as strictly type specific. To study selection pressures acting on the identified immunogenic domains, structural constraints and distribution of synonymous and nonsynonymous mutations (amino acids, unchanged or changed) were analyzed. Two linear B epitopes (SU3 and TM4) appeared to be submitted to pos. selection for change, a pattern of evolution predicting their possible involvement in antiviral protection. These expts. provide a pertinent choice of oligopeptides for further anal. of the protective response against **FIV** envelope glycoproteins, as a model to understand the role of antibody escape in lentiviral persistence, and to design feline AIDS **vaccines**.

L3 ANSWER 19 OF 29 CA COPYRIGHT 1995 ACS

AN 118:229926 CA

TI Identification of a region in the Pr55gag-polyprotein essential for HIV-1 particle formation

SO Virology (1993), 193(2), 981-5

CODEN: VIRLAX; ISSN: 0042-6822

AU von Pöblotzki, Andreas; Wagner, Ralf; Niedrig, Matthias; Wanner, Gerhard; Wolf, Hans; Modrow, Susanne

PY 1993

AB The pr55gag polyprotein of HIV-1 plays a crit. role in the formation

of immature virus particles in the cell and during the budding process. The influence of amino acid substitutions in the p24CA region of the gag polyprotein on the viral assembly process was investigated. Deletion of the amino acids 341-352 in the carboxy terminal part of the p24CA resulted in a loss of the capacity of the gag polyprotein to form virus-like particles when expressed in eucaryotic cells by recombinant **vaccinia** virus. In further expts., it turned out that the amino acids 341-346 and 350-352 are important for the ability of the pr55gag to form virus-like particles. Because these stretches are conserved among HIV-1, HIV-2, SIV, and **FIV**, it was concluded that these amino acids form a domain highly important for the assembly of these lentiviruses.

L3 ANSWER 20 OF 29 CA COPYRIGHT 1995 ACS

AN 118:146090 CA

TI Feline lymphoid cell lines capable of producing **feline immunodeficiency virus (FIV)**, and **vaccines** against **FIV**

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

IN Yamamoto, Janet K.

PI WO 9301278 A1 930121

AI WO 92-US5571 920701

PY 1993

AB The title cell lines are disclosed, as are **vaccines** comprising either the inactivated cell lines or inactivated or attenuated **FIV** therefrom. Interleukin-2 (IL-2)-independent **FIV**-producing cell lines (FL-4 and FL-6) were developed by gradual depletion of IL-2 from **FIV**-FeT1 cells. The FL-4 and FL-6 lines produced larger amts. of viral antigens than the parent cell line. Virus preps. from FL-4 and FL-6 were highly infectious in both in vitro and in vivo systems. Immunization of cats with inactivated FL-4 preps. led to the prodn. of anti-**FIV** antibodies specific for the viral core protein p28 soon after the 2nd immunization; antibodies to other viral antigens were demonstrated only after the 3rd or 4th immunization. Effective protection against **FIV** challenge could also be achieved with an inactivated whole-virus **vaccine**.

L3 ANSWER 21 OF 29 CA COPYRIGHT 1995 ACS

AN 117:210509 CA

TI Analysis of the amino terminal presequence of the **feline immunodeficiency virus** glycoprotein: effect of deletions on the intracellular transport of gp95

SO Virology (1992), 190(2), 569-78

CODEN: VIRLAX; ISSN: 0042-6822

AU Stephens, E. B.; Butfiloski, E. J.; Monck, E.

PY 1992

AB The envelope glycoprotein of **feline**

**immunodeficiency virus (FIV)** consists of two noncovalently assocd. subunits, the surface glycoprotein (SU; gp95) and the transmembrane glycoprotein (TM; gp40). An unusual feature of the open reading frame (ORF) encoding the **FIV** glycoprotein is the presence of an unusually long amino terminal sequence (149 amino acids, "L" region or n-region of the signal sequence) preceding the predicted hydrophobic signal sequence. In

order to examine the role of this n-region in the biosynthesis of gp95, the gene-encoding signal sequence and the surface glycoprotein (gp95) were expressed using recombinant **vaccinia** viruses. Glycoprotein mutants were constructed with 25, 42, 73, 102, and 147 amino acids removed from the n-region. Expression studies revealed that deletion of 25-102 amino acids did not appreciably affect the biosynthesis, intracellular transport, and release of gp95 from the cell surface. In contrast, removal of 147 of 149 amino acids resulted in gp95 that was blocked in release from the cell. These results indicate that between 3 and 47 amino acids of the n-region are required for the proper biosynthesis, processing, and release of the **FIV** gp95 from infected cells.

L3 ANSWER 22 OF 29 CA COPYRIGHT 1995 ACS

AN 117:206377 CA

TI Recombinant **feline immunodeficiency**

**virus** glycoprotein 160 and p24 gag protein

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

IN Young, Eli; Davis, Deborah; Storey, James R.; Beltz, Gerald

PI WO 9215684 A1 920917

AI WO 92-US1421 920227

PY 1992

AB The gp 160 envelope protein, the p24 gag protein, and their fragments of **feline immunodeficiency**

**virus (FIV)** are expressed in and purified from

host cells. These antigen and their antibody can be used for detection of **FIV** by immunoassay or used as a therapeutic agent for treatment of prevention of the **FIV**-assocd.

diseases. A 0.4-kb fragment of the gene for gp160 was obtained by PCR using the primers derived from the envelope-coding region 8178-8576 and cloned into an Escherichia coli expression vector pLCBCO to obtain pLCBCOFIV0.4. The 0.4-kb gene protein purified from the transformed E. coli was used for diagnosis of cats infected by **FIV** by Western blot.

L3 ANSWER 23 OF 29 CA COPYRIGHT 1995 ACS

AN 117:189758 CA

TI Major core proteins, p24s, of human, simian, and feline immunodeficiency viruses are partly expressed on the surface of the virus-infected cells

SO Vaccine (1992), 10(10), 677-83

CODEN: VACCDE; ISSN: 0264-410X

AU Nishino, Yoshii; Ohki, Kohji; Kimura, Takuro; Morikawa, Shigeru; Mikami, Takeshi; Ikuta, Kazuyoshi

PY 1992

AB The authors have previously shown the expression of human immunodeficiency virus type 1 (HIV-1) major gag protein, p24, on the surface of persistently HIV-1-infected cells by using murine monoclonal antibodies (mAb). They now report that the cell surface gag p24 antigen expression is a universal phenomenon among HIV-1, simian immunodeficiency virus (SIV), and **feline**

**immunodeficiency virus (FIV)**. The mAbs

prepd. by immunization with purified HIV-1 particles were used as antibodies cross-reactive to HIV-1 and SIVagmp24 antigens. The mAbs to **FIV** p24 were raised against the gag precursor 50 kDa protein of **FIV**, which was expressed by baculovirus vector.

The p24 antigen expression on the cell surface was detectable in certain combinations of virus-host cell systems in all of these viruses. Since these p24 regions of the animal viruses seem to play as important a role in cell-mediated immunity as that of HIV-1, the p24 applicability as a candidate epitope for **vaccine** development could be evaluated in those animals.

L3 ANSWER 24 OF 29 CA COPYRIGHT 1995 ACS

AN 117:24666 CA

TI Immunologic responses in healthy random-source cats fed N,N-dimethylglycine-supplemented diets

SO Am. J. Vet. Res. (1992), 53(5), 829-33

CODEN: AJVRAH; ISSN: 0002-9645

AU Weiss, Richard C.

PY 1992

AB The immunomodulatory capacities of N,N-dimethylglycine (DMG) were examd. in random-source cats. Blood mononuclear leukocytes of healthy adult cats that had neg. results to tests for FeLV and **feline immunodeficiency virus** were

exposed in vitro to various concns. of DMG (10-1000 .mu.g/mL) and were evaluated for proliferative responses to T- or B-cell phyto mitogens. Although increased, mean lymphocyte blastogenic responses to phytolectins in DMG-treated cultures did not differ from responses of untreated cultures. For in vivo studies, cats were given a soln. contg. either 100 mg of DMG or a control soln. without DMG orally at 8 AM and 6 PM for 40 consecutive days. On post-treatment day 24 and 25, mean blastogenic responses to phytolectins in DMG-treated and control cats inoculated 10 days earlier with an inactivated feline virus **vaccine** were similar. Cats given DMG and inoculated twice in a 3-wk interval with a com. **vaccine** contg. inactivated feline herpesvirus-1 and feline calicivirus had lower virus neutralizing serum antibody titers against feline herpesvirus-1, compared with titers of control cats, whereas feline calicivirus titers were similar in both groups. On day 25, mean serum interferon activity, induced after i.v. inoculation of Newcastle-disease virus, was lower in the DMG-treated cats. Results of this study of DMG in healthy cats failed to demonstrate enhancement of either specific or nonspecific immunity.

L3 ANSWER 25 OF 29 CA COPYRIGHT 1995 ACS

AN 116:167664 CA

TI Cloning and sequence determination of the feline calicivirus strain F9

SO Biochem. Soc. Trans. (1992), 20(1), 26S

CODEN: BCSTB5; ISSN: 0300-5127

AU Meanger, J.; Carter, M. J.; Gaskell, R. M.; Turner, P. C.

PY 1992

AB The mol. biol. of feline calicivirus (FCV) is not well understood. FCV are small, nonenveloped viruses which contain a pos. stranded RNA genome. Two strains have now been partially cloned and sequenced; one in the USA (CF1/68 **FIV** (FCV); and another (**vaccine** strain F9) in the UK. The UK **vaccine**

strain F9 that was cloned here may be smaller with a size of 7 kb compared to the 8 kb described for the American isolate. To date, 5284 bp of cDNA were sequenced from the polyadenylated 3'-end of the virus genome towards the 5'-end. This region contains four

candidate open reading frames (ORFs) designated from the 3'-end. Three are complete and comprise ORF1 of 246, ORF2 of 2013 and ORF3 of 318 nucleotides. The fourth, ORF4, present in the same frame as ORF2 extends beyond the sequenced region towards the 5' end of the viral genome and is at least 3000 bp in size. It was previously shown that ORF2 encodes the precursor of the capsid protein, 671 amino acids long and some 73,441 in mol. wt., which loses 124 residues at the N-terminus during maturation. Although the coding assignment for ORF3 is not yet certain it appears to correspond to the putative non-structural gene identified previously. The capsid sequence derived from strain F9 and that reported for strain CF1/68 **FIV** reveals that this protein contains both highly conserved and more variable regions. The latter may be responsible for the obsd. antigenic and pathogenic divergence between strains of FCV.

L3 ANSWER 26 OF 29 CA COPYRIGHT 1995 ACS  
 AN 115:225453 CA  
 TI Recombinant adenoviruses for producing vaccines  
 SO PCT Int. Appl., 17 pp.  
 CODEN: PIXXD2  
 IN Spibey, Norman  
 PI WO 9111525 A2 910808  
 AI WO 91-GB107 910125  
 PY 1991  
 AB A recombinant canine adenovirus acting as a vector for an antigen-producing gene (e.g. a rabies glycoprotein gene) comprises a CAV-2 strain modified to contain the promoter-gene sequence within the region from the SmaI site close to the end of the inverted terminal repeat up to the promoter for the early region 4 (E4). To assist replication the recombinant virus is transfected into a cell line expressing Ela proteins. The recombinant virus is used for the prodn. of a corresponding vaccine.

L3 ANSWER 27 OF 29 CA COPYRIGHT 1995 ACS  
 AN 115:69818 CA  
 TI Antigenic polypeptides of feline T-cell lymphotropic lentivirus (**FIV**), monoclonal antibodies to **FIV** polypeptides, cloning of the polypeptides, immunoassay for anti-**FIV** antibody detection, and use of the polypeptides for vaccines  
 SO PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 IN Anderson, Philip R. Andersen; O'Connor, Thomas P.; Tonelli, Quentin J.  
 PI WO 9013573 A1 901115  
 AI WO 90-US2338 900430  
 PY 1990  
 AB The purified polypeptides of the invention contain an epitope of an antigenic **FIV** polypeptide. The polypeptide may be glycosylated or nonglycosylated and may be a fragment of .gtoreq.5 amino acids or a polypeptide naturally occurring in **FIV** particles. The fragment may be obtained from a naturally occurring polypeptide, e.g. by enzymic digestion, or may be produced by recombinant techniques. Thus, **FIV** gag polypeptides were isolated and purified; sequences of peptides of p10, p15, and p26 were detd. Monoclonal antibodies to **FIV** polypeptides were produced by std. hybridoma technol. Mol. cloning of **FIV** polypeptides is described, as is an immunoassay using the

polypeptides of the invention to detect anti-FIV antibodies in cats. The polypeptides are also useful for vaccines.

L3 ANSWER 28 OF 29 CA COPYRIGHT 1995 ACS

AN 113:76350 CA

TI Coinfection of cats with FIV and FeLV affects both quantity and distribution of FIV DNA in various tissues

SO Vaccines 90: Mod. Approaches New Vaccines Incl. Prev. AIDS, [Conf.], 7th (1990), Meeting Date 1989, 375-8. Editor(s): Brown, Fred. Publisher: Cold Spring Harbor Lab., Cold Spring Harbor, N. Y. CODEN: 56UPAE

AU Torten, Michael; Sparger, E. Elizabeth; Rideout, Bruce A.; Pedersen, Niels C.; Luciw, Paul A.

PY 1990

AB The time span of latency in acquired immunodeficiency diseases makes it difficult to evaluate vaccines and drugs. Redn. of the latency period would increase the value of an animal model. In this report, coinfection of cats with feline

**immunodeficiency virus (FIV)** and feline

leukemia virus (FeLV) led to rapid development of FAIDS. Using the polymerase chain reaction techniques, FIV DNA was shown to be present in kidney, liver, intestine, and brain as a result of FeLV coinfection. The level of FeLV P27 antigen expression in coinfecting cats was similar to that in cats infected only with FeLV.

L3 ANSWER 29 OF 29 CA COPYRIGHT 1995 ACS

AN 110:207153 CA

TI Molecular cloning of **feline immunodeficiency virus**

SO Proc. Natl. Acad. Sci. U. S. A. (1989), 86(7), 2448-52  
CODEN: PNASA6; ISSN: 0027-8424

AU Olmsted, Robert A.; Barnes, Andrea K.; Yamamoto, Janet K.; Hirsch, Vanessa M.; Purcell, Robert H.; Johnson, Philip R.

PY 1989

AB **Feline immunodeficiency virus (**

**FIV)** is a T-lymphotropic retrovirus assocd. with

immunodeficiency and opportunistic infections in cats. The discovery of FIV provides an opportunity for the development of a small animal model for AIDS. To initiate the mol. and biol. characterization of FIV, cDNA clones were synthesized and used to isolate a proviral clone of FIV. Mol.

cross-hybridization anal. of FIV with 5 lentiviruses

revealed that nucleotide sequence similarities exist between

FIV and these lentiviruses in the gag-pol genes. However, nucleotide sequence similarities were not seen upon comparison of the FIV long terminal repeat sequence with known viral sequences. Common antigenic determinants appeared to be shared by

FIV, caprine arthritis encephalitis virus, and visna virus, as shown by serol. cross-reactivity of rabbit antibodies to caprine arthritis encephalitis virus and visna virus with the putative

FIV core protein p28. These studies demonstrated that

FIV is a member of the lentivirus subfamily and is distantly related to the AIDS lentiviruses of primates. Importantly, progeny virions of the mol. clone were infectious for exptl. inoculated cats. The availability of an infectious mol. clone will make possible a detailed dissection of the mol. pathogenesis of



**FIV**, which may facilitate the development of **vaccine** and therapeutic strategies for AIDS.

3030 IMMUNOGEN  
64001 IMMUNE  
951387 RESPONSE  
15137 IMMUNE RESPONSE  
(IMMUNE(W)RESPONSE)

L4 1 IMMUNOGEN AND IMMUNE RESPONSE AND L2

=> s 14 not 13

L5 0 L4 NOT L3

=> s yamamoto j?/au

L6 788 YAMAMOTO J?/AU

=> s pedersen n?/au

L7 186 PEDERSEN N?/AU

=> s 16 and 17

L8 6 L6 AND L7

=> s 18 not 13

L9 5 L8 NOT L3

=> d 1-5 an .mh;fil .biotech,wpids,vetb,vetu,lifesci

L9 ANSWER 1 OF 5 CA COPYRIGHT 1995 ACS

AN 115:154958 CA

TI Feline t-lymphotropic lentivirus

SO U.S., 11 pp. Cont. of U.S. Ser. No. 89,700, abandoned.

CODEN: USXXAM

IN **Pedersen, Niels C.; Yamamoto, Janet K.**

PI US 5037753 A 910806

AI US 90-618030 901116

PY 1991

AB Feline T-lymphotropic lentivirus (FTLV) is isolated from in vitro cell cultures. These FTLV isolates provide material useful in diagnosis of and vaccination against FTLV infection. ELISA and indirect immunofluorescence assays for HTLV antibodies were described and an inactivated FTLV useful as a whole virus vaccine was prepd.

L9 ANSWER 2 OF 5 CA COPYRIGHT 1995 ACS

AN 110:210804 CA

TI Production of defective retroviruses using interferon, vaccines containing the defective viruses by themselves or in combination with interferon, and a novel feline interferon

SO Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

IN **Pedersen, Neils C.; Yamamoto, Janet**

PI EP 255242 A2 880203

AI EP 87-305834 870701

PY 1988

AB Retroviral vaccines comprise incompetent retroviruses contg. defective RNA produced by growing virally transformed cells in the presence of interferon. The resulting defective viruses by

themselves or in combination with interferon can be used as vaccines for immunizing virus-sensitive hosts against infection. A novel feline interferon is produced in culture with cells infected with the defective noninfectious retroviruses. Lymphosarcoma (LSA-1) cells were derived from a thymic tumor induced in a 1-yr-old cat by Snyder-Theilen feline leukemia virus (ST-FeLV). Kittens were vaccinated i.m. or i.p. with LSA-1 culture fluid which contained both virus structural proteins and interferon. Kittens vaccinated i.p. showed lower levels of post-challenge viremia than kittens vaccinated i.m. (1:6 vs 3:6, resp.). Nonvaccinated littermates showed persistent post-challenge infection in 5 out of 6 cases. Tissue culture fluid will normally contain 300-3000 units .alpha.-interferon/mL which may be used in the prepn. of vaccines. About 0.5-2 mL of the vaccine may be injected, with .gtoreq.1 booster shots at 3-4-wk intervals followed by annual immunizations. Procedures for characterization of LSA cells, virus, and feline interferons are given.

L9 ANSWER 3 OF 5 CA COPYRIGHT 1995 ACS

AN 105:40857 CA

TI Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2

SO J. Interferon Res. (1986), 6(2), 143-52

CODEN: JIREDJ; ISSN: 0197-8357

AU Yamamoto, Janet K.; Barre-Sinoussi, Francoise; Bolton, Veronica; Pedersen, Niels C.; Gardner, Murray B.

PY 1986

AB The effect of human interferons (IFNs) (.alpha., .beta., and .gamma.) on the in vitro replication of AIDS retroviruses (LAV, HTLV-III, and ARV-2) in human peripheral blood lymphocytes was investigated. At the time of peak virus prodn., IFN-.alpha. prepn. (leukocyte, Namalwa, .alpha.1, and .alpha.2) at 100 units (U)/mL, suppressed LAV, HTLV-III, and ARV-2 replication as measured by reverse transcriptase (RT) activity by >50%. This suppression was dose-dependent and high dosages (500 U/mL) of IFN-.alpha. resulted in almost complete suppression of RT activities (77-99%). A low dose (100 U/mL) of IFN-.beta. suppressed all 3 AIDS viruses by 75%. In contrast, human IFN-.gamma. at a dose range from 100 U/mL to 500 U/mL had no effect on the prodn. of infectious viruses. Thus, only IFN-.alpha. and -.beta. are effective against LAV, HTLV-III, and ARV-2 replication. A continuous supply of IFN appeared to be essential for the const. suppression of RT activity. Upon termination of single IFN treatment, enhanced virus prodn. resulted.

L9 ANSWER 4 OF 5 CA COPYRIGHT 1995 ACS

AN 104:166665 CA

TI A feline retrovirus induced T-lymphoblastoid cell-line that produces an atypical alpha type of interferon

SO Vet. Immunol. Immunopathol. (1986), 11(1), 1-19

CODEN: VIIMDS; ISSN: 0165-2427

AU Yamamoto, J. K.; Ho, E.; Pedersen, N. C.

PY 1986

AB A cell-line, designated LSA-1, was derived from a thymic lymphosarcoma that occurred in a cat with exptl. induced feline leukemia virus (FeLV) infection. LSA-1 cells possessed surface receptors and antigens of normal T-lymphocytes, but were unresponsive to interleukin-2 stimulation. The LSA cell-line

constitutively produced and released an interferon into the culture supernatants. Unlike .alpha. and .beta.-interferons, which were acid, SDS, and heat stable, LSA interferon was acid labile and SDS and heat stable. In comparison, std. feline .gamma.-interferon was acid, SDS, and heat labile. LSA interferon had a mol. wt. of 20,000 daltons, compared to 17,000-19,000 daltons for .gamma.-, 19,000-25,000 for .beta.-, and 25,000-45,000 daltons for .alpha.-interferons. Std. feline interferons were active only on cat cell lines, with the exceptions of .alpha.-interferon, which also reacted with MDCK canine cells. LSA interferon resembled the std. feline .alpha.-interferon because it also reacted with feline and canine cells. Thus, LSA interferon is an atypical acid labile .alpha.-interferon, resembling in this respect the abnormal .alpha.-interferon seen in humans with AIDS and lupus, and mice with retrovirus infections. LSA-1 cells produced high levels of FeLV structural proteins but very little infectious virus. This effect was due to endogenously produced interferon; LSA cell clones that were selected for low interferon prodn. produced much higher levels of infectious FeLV than parent cells or clones selected for high interferon prodn. Cat cells pretreated with LSA or with std. feline .alpha.- and .beta.-interferons, and then infected with FeLV, produced high levels of FeLV proteins but very little infectious virus.

L9 ANSWER 5 OF 5 CA COPYRIGHT 1995 ACS  
 AN 103:176734 CA  
 TI Molecular comparison of retroviruses associated with human and simian AIDS  
 SO Hematol. Oncol. (1985), 3(3), 187-97  
 CODEN: HAONDL; ISSN: 0278-0232  
 AU Bryant, M. L.; Yamamoto, J.; Luciw, P.; Munn, R.; Marx, P.; Higgins, J.; Pedersen, N.; Levine, A.; Gardner, M. B.  
 PY 1985  
 AB Infectious retrovirus(es) assocd. with the human (LAV, HTLV-III, ARV) and simian (SAIDS-1) acquired immune deficiency syndrome were compared by electron microscopy, immunofluorescence and immunoblotting techniques and by restriction endonuclease mapping of the viral genomes. The extracellular virus particles had similar type D morphol., but intracytoplasmic type A nucleoids were found only in SAIDS virus infected cells. Although the antigens of the 3 prototype AIDS viruses were similar, no cross-reactivity with the SAIDS virus was detected. Mol. hybridization and restriction enzyme anal. also revealed that the SAIDS and AIDS viruses were genetically unrelated. However, only minor differences, consistent with strain polymorphism, were found between the 3 AIDS virus isolates. Thus, the retroviruses assocd. with AIDS in macaques and humans are unique to each species.

FILE 'BIOSIS' ENTERED AT 11:28:33 ON 21 MAR 95  
 COPYRIGHT (C) 1995 BIOSIS(R)

FILE 'MEDLINE' ENTERED AT 11:28:33 ON 21 MAR 95

FILE 'EMBASE' ENTERED AT 11:28:33 ON 21 MAR 95  
 COPYRIGHT (C) 1995 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 11:28:33 ON 21 MAR 95  
COPYRIGHT (C) 1995 DERWENT INFORMATION LTD

FILE 'VETB' ENTERED AT 11:28:33 ON 21 MAR 95  
COPYRIGHT (C) 1995 DERWENT INFORMATION LTD

FILE 'VETU' ENTERED AT 11:28:33 ON 21 MAR 95  
COPYRIGHT (C) 1995 DERWENT INFORMATION LTD

FILE 'LIFESCI' ENTERED AT 11:28:33 ON 21 MAR 95  
COPYRIGHT (C) 1995 Cambridge Scientific Abstracts (CSA)

=> s (fiv or feline immunodeficien? virus)

FILE 'BIOSIS'

343 FIV  
6853 FELINE  
86986 IMMUNODEFICIEN?  
277353 VIRUS  
480 FELINE IMMUNODEFICIEN? VIRUS  
(FELINE(W)IMMUNODEFICIEN?(W)VIRUS)  
L10 543 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

FILE 'MEDLINE'

350 FIV  
5785 FELINE  
59493 IMMUNODEFICIEN?  
201538 VIRUS  
342 FELINE IMMUNODEFICIEN? VIRUS  
(FELINE(W)IMMUNODEFICIEN?(W)VIRUS)  
L11 435 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

FILE 'EMBASE'

323 FIV  
4080 "FELINE"  
49024 IMMUNODEFICIEN?  
234037 "VIRUS"  
255 FELINE IMMUNODEFICIEN? VIRUS  
(FELINE(W)IMMUNODEFICIEN?(W)"VIRUS")  
L12 379 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

FILE 'WPIDS'

40 FIV  
301 FELINE  
924 IMMUNODEFICIEN?  
11297 VIRUS  
28 FELINE IMMUNODEFICIEN? VIRUS  
(FELINE(W)IMMUNODEFICIEN?(W)VIRUS)  
L13 50 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

FILE 'VETB'

0 FIV  
455 FELINE  
23 IMMUNODEFICIEN?  
9963 VIRUS  
0 FELINE IMMUNODEFICIEN? VIRUS  
(FELINE(W)IMMUNODEFICIEN?(W)VIRUS)

L14 0 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

FILE 'VETU'

123 FIV  
874 FELINE  
289 IMMUNODEFICIEN?  
6374 VIRUS  
96 FELINE IMMUNODEFICIEN? VIRUS  
(FELINE(W)IMMUNODEFICIEN?(W)VIRUS)

L15 133 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

FILE 'LIFESCI'

208 FIV  
1978 "FELINE"  
21090 IMMUNODEFICIEN?  
89242 "VIRUS"  
240 FELINE IMMUNODEFICIEN? VIRUS  
("FELINE"(W)IMMUNODEFICIEN?(W)"VIRUS")

L16 257 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

TOTAL FOR ALL FILES

L17 1797 (FIV OR FELINE IMMUNODEFICIEN? VIRUS)

=> s l17 and vaccin?

FILE 'BIOSIS'

59077 VACCIN?

L18 51 L10 AND VACCIN?

FILE 'MEDLINE'

73282 VACCIN?

L19 44 L11 AND VACCIN?

FILE 'EMBASE'

57856 VACCIN?

L20 48 L12 AND VACCIN?

FILE 'WPIDS'

6651 VACCIN?

L21 17 L13 AND VACCIN?

FILE 'VETB'

8759 VACCIN?

L22 0 L14 AND VACCIN?

FILE 'VETU'

7854 VACCIN?

L23 40 L15 AND VACCIN?

FILE 'LIFESCI'

18581 VACCIN?

L24 29 L16 AND VACCIN?

TOTAL FOR ALL FILES

L25 229 L17 AND VACCIN?

=> s yamamoto j?/au

FILE 'BIOSIS'

L26            432 YAMAMOTO J?/AU

FILE 'MEDLINE'

L27            372 YAMAMOTO J?/AU

FILE 'EMBASE'

L28            336 YAMAMOTO J?/AU

FILE 'WPIDS'

L29            58 YAMAMOTO J?/AU

FILE 'VETB'

L30            0 YAMAMOTO J?/AU

FILE 'VETU'

L31            8 YAMAMOTO J?/AU

FILE 'LIFESCI'

L32            71 YAMAMOTO J?/AU

TOTAL FOR ALL FILES

L33            1277 YAMAMOTO J?/AU

=> s pedersen n?/au

FILE 'BIOSIS'

L34            425 PEDERSEN N?/AU

FILE 'MEDLINE'

L35            385 PEDERSEN N?/AU

FILE 'EMBASE'

L36            263 PEDERSEN N?/AU

FILE 'WPIDS'

L37            24 PEDERSEN N?/AU

FILE 'VETB'

L38            7 PEDERSEN N?/AU

FILE 'VETU'

L39            11 PEDERSEN N?/AU

FILE 'LIFESCI'

L40            144 PEDERSEN N?/AU

TOTAL FOR ALL FILES

L41            1259 PEDERSEN N?/AU

=> s l41 and l33

FILE 'BIOSIS'

L42            15 L34 AND L26

FILE 'MEDLINE'

L43            12 L35 AND L27

FILE 'EMBASE'

L44            9 L36 AND L28

FILE 'WPIDS'  
L45 3 L37 AND L29

FILE 'VETB'  
L46 0 L38 AND L30

FILE 'VETU'  
L47 0 L39 AND L31

FILE 'LIFESCI'  
L48 13 L40 AND L32

TOTAL FOR ALL FILES  
L49 52 L41 AND L33

=> s 117 and 149

FILE 'BIOSIS'  
L50 9 L10 AND L42

FILE 'MEDLINE'  
L51 7 L11 AND L43

FILE 'EMBASE'  
L52 6 L12 AND L44

FILE 'WPIDS'  
L53 1 L13 AND L45

FILE 'VETB'  
L54 0 L14 AND L46

FILE 'VETU'  
L55 0 L15 AND L47

FILE 'LIFESCI'  
L56 8 L16 AND L48

TOTAL FOR ALL FILES  
L57 31 L17 AND L49

=> dup rem 157

DUPLICATE IS NOT AVAILABLE IN 'WPIDS'. ANSWERS FROM THESE FILES WILL BE  
CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L57

L58 15 DUP REM L57 (16 DUPLICATES REMOVED)

=> d 1-15

L58 ANSWER 1 OF 15 LIFESCI COPYRIGHT 1995 CSA

AN 94:20931 LIFESCI

TI Methods and compositions for vaccinating against **feline  
immunodeficiency virus**

AU Yamamoto, J.K.; Pedersen, N.C.

CS Regents Univ. California, Oakland, CA (USA)

SO (1994) . US Patent 5,275,813; US Cl. 424/89; Int. Cl. A61K 39/12..

DT Patent

FS V; W2  
LA English

L58 ANSWER 2 OF 15 EMBASE COPYRIGHT 1995 ELSEVIER SCI. B.V.  
AN 92329404 EMBASE  
TI SIV and FIV vaccine studies at UC Davis: 1991 update.  
AU Gardner M.; Yamamoto J.; Marthas M.; Miller C.; Jennings  
M.; Rosenthal A.; Luciw P.; Planelles V.; Yilma T.; Giavedoni L.;  
Ahmed S.; Steimer K.; Haigwood N.; Pedersen N.  
CS Department of Medical Pathology, University of California, Davis,  
CA, United States  
SO AIDS RES. HUM. RETROVIRUSES, (1992) 8/8 (1495-1498).  
ISSN: 0889-2229 CODEN: ARHRE7  
CY United States  
DT Journal  
FS 004 Microbiology  
026 Immunology, Serology and Transplantation  
030 Pharmacology  
037 Drug Literature Index  
LA English

L58 ANSWER 3 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 1  
AN 91:5941 BIOSIS  
DN BA91:5941  
TI IMMUNOLOGIC ABNORMALITIES IN PATHOGEN-FREE CATS EXPERIMENTALLY  
INFECTED WITH **FELINE IMMUNODEFICIENCY  
VIRUS.**  
AU ACKLEY C D; YAMAMOTO J K; LEVY N; PEDERSEN N C;  
COOPER M D  
CS DIV. DEVELOPMENTAL CLINICAL IMMUNOL., DEP. MEDICINE, COMPREHENSIVE  
CANCER CENT., UNIV. ALA., BIRMINGHAM, ALABAMA 35294.  
SO J VIROL 64 (11). 1990. 5652-5655. CODEN: JOVIAM ISSN: 0022-538X  
LA English

L58 ANSWER 4 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 2  
AN 90:133434 BIOSIS  
DN BA89:72245  
TI FELINE LEUKEMIA VIRUS INFECTION AS A POTENTIATING COFACTOR FOR THE  
PRIMARY AND SECONDARY STAGES OF EXPERIMENTALLY INDUCED **FELINE  
IMMUNODEFICIENCY VIRUS** INFECTION.  
AU PEDERSEN N C; TORTEN M; RIDEOUT B; SPARGER E; TONACHINI T;  
LUCIW P A; ACKLEY C; LEVY N; YAMAMOTO J  
CS DEP. MED., SCH. VET. MED., UNIV. CALIF., DAVIS, CALIF. 95616.  
SO J VIROL 64 (2). 1990. 598-606. CODEN: JOVIAM ISSN: 0022-538X  
LA English

L58 ANSWER 5 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS  
AN 90:188341 BIOSIS  
DN BR38:88664  
TI **FELINE IMMUNODEFICIENCY VIRUS** GENETIC  
ORGANIZATION AND REGULATION.  
AU LUCIW P A; ELDER J; TALBOTT R; SPARGER E; YAMAMOTO J;  
**PEDERSEN N**  
CS UNIV. CALIF., DAVIS, CA.  
SO ANNUAL MEETING OF THE NATIONAL CANCER INSTITUTE LABORATORY OF TUMOR  
CELL BIOLOGY, BETHESDA, MARYLAND, USA, AUGUST 20-26, 1989. AIDS RES  
HUM RETROVIRUSES 6 (1). 1990. 79. CODEN: ARHRE7 ISSN: 0889-2229



DT Conference  
LA English

L58 ANSWER 6 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS  
AN 90:188323 BIOSIS  
DN BR38:88646  
TI PATHOGENESIS AND VACCINE STUDIES IN SIV INFECTED MACAQUES AND  
FIV INFECTED CATS.  
AU GARDNER M B; LUCIW P; MARX P; MCGRAW T; CARLSON J; YAMAMOTO J  
; PEDERSEN N  
CS DEP. MED. PATHOL., CALIF. PRIMATE RES. CENT., UNIV. CALIFORNIA DAVIS,  
CA 95616.  
SO ANNUAL MEETING OF THE NATIONAL CANCER INSTITUTE LABORATORY OF TUMOR  
CELL BIOLOGY, BETHESDA, MARYLAND, USA, AUGUST 20-26, 1989. AIDS RES  
HUM RETROVIRUSES 6 (1). 1990. 69. CODEN: ARHRE7 ISSN: 0889-2229  
DT Conference  
LA English

L58 ANSWER 7 OF 15 MEDLINE DUPLICATE 3  
AN 89234538 MEDLINE  
TI Development and evaluation of immunoassay for detection of  
antibodies to the feline T-lymphotropic lentivirus (**feline  
immunodeficiency virus**).  
AU O'Connor T P Jr; Tanguay S; Steinman R; Smith R; Barr M C;  
Yamamoto J K; Pedersen N C; Andersen P R; Tonelli  
Q J  
CS IDEXX Corp., Portland, Maine 04101.  
SO J Clin Microbiol, (1989 Mar) 27 (3) 474-9.  
Journal code: HSH. ISSN: 0095-1137.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 8908

L58 ANSWER 8 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 4  
AN 89:137399 BIOSIS  
DN BA87:72052  
TI EPIDEMIOLOGIC AND CLINICAL ASPECTS OF **FELINE  
IMMUNODEFICIENCY VIRUS** INFECTION IN CATS FROM THE  
CONTINENTAL USA AND CANADA AND POSSIBLE MODE OF TRANSMISSION.  
AU YAMAMOTO J K; HANSEN H; HO E W; MORISHITA T Y; OKUDA T;  
SAWA T R; NAKAMURA R M; PEDERSEN N C  
CS DEP. MED., SCH. VET. MED., UNIV. CALIF., DAVIS, CALIF. 95616.  
SO J AM VET MED ASSOC 194 (2). 1989. 213-220. CODEN: JAVMA4 ISSN:  
0003-1488  
LA English

L58 ANSWER 9 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 5  
AN 89:413116 BIOSIS  
DN BR37:68579  
TI **FELINE IMMUNODEFICIENCY VIRUS**  
INFECTION.  
AU PEDERSEN N C; YAMAMOTO J K; ISHIDA T; HANSEN H  
CS DEP. MED., SCH. VET. MED., UNIV. CALIF., DAVIS, CALIF. 95616.  
SO VET IMMUNOL IMMUNOPATHOL 21 (1). 1989. 111-129. CODEN: VIIMDS ISSN:  
0165-2427

LA English

L58 ANSWER 10 OF 15 MEDLINE DUPLICATE 6  
 AN 90121986 MEDLINE  
 TI **Feline immunodeficiency virus** is a  
 lentivirus associated with an AIDS-like disease in cats.  
 AU Sparger E E; Luciw P A; Elder J H; Yamamoto J K;  
 Lowenstine L J; Pedersen N C  
 CS Department of Medicine, School of Veterinary Medicine, University of  
 California, Davis 95616.  
 SO AIDS, (1989) 3 Suppl 1 S43-9. Ref: 49  
 Journal code: AID. ISSN: 0269-9370.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LA English  
 FS Priority Journals  
 EM 9005

L58 ANSWER 11 OF 15 EMBASE COPYRIGHT 1995 ELSEVIER SCI. B.V.  
 AN 90017856 EMBASE  
 TI **Feline immunodeficiency virus** is a  
 lentivirus associated with an AIDS-like disease in cats.  
 AU Sparger E.E.; Luciw P.A.; Elder J.H.; Yamamoto J.K.;  
 Lowenstine L.J.; Pedersen N.C.  
 CS Department of Medicine, School of Veterinary Medicine, University of  
 California, Davis, CA 95616, United States  
 SO AIDS, (1989) 3/SUPPL. 1 (S43-S49).  
 ISSN: 0269-9370 CODEN: AIDSET  
 CY United Kingdom  
 DT Journal  
 FS 026 Immunology, Serology and Transplantation  
 047 Virology  
 LA English

L58 ANSWER 12 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 7  
 AN 88:419338 BIOSIS  
 DN BA86:81950  
 TI PATHOGENESIS OF EXPERIMENTALLY INDUCED **FELINE**  
**IMMUNODEFICIENCY VIRUS** INFECTION IN CATS.  
 AU **YAMAMOTO J K**; SPARGER E; HO E W; ANDERSEN P R; O'CONNOR T  
 P; MANDELL C P; LOWENSTINE L; MUNN R; **PEDERSEN N C**  
 CS DEP. MED., SCH. VET. MED., UNIV. CALIFORNIA, DAVIS, CALIF. 95616.  
 SO AM J VET RES 49 (8). 1988. 1246-1258. CODEN: AJVRAH ISSN: 0002-9645  
 LA English

L58 ANSWER 13 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS  
 AN 89:119887 BIOSIS  
 DN BR36:65303  
 TI **FELINE IMMUNODEFICIENCY SYNDROME** A COMPARISON BETWEEN **FELINE**  
**T-LYMPHOTROPIC LENTIVIRUS** AND **FELINE LEUKEMIA VIRUS**.  
 AU **YAMAMOTO J K**; **PEDERSEN N C**; HO E W; OKUDA T;  
 THEILEN G H  
 CS DEP. SURG., SCH. VET. MED., UNIV. CALIFORNIA, DAVIS, CALIF. 95616.  
 SO XIIIITH SYMPOSIUM OF THE INTERNATIONAL ASSOCIATION FOR COMPARATIVE  
 RESEARCH ON LEUKEMIA AND RELATED DISEASES, JERUSALEM, ISRAEL,

NOVEMBER 8-13, 1987. LEUKEMIA (BALTIMORE) 2 (12 SUPPL.). 1988.  
204S-215S. CODEN: LEUKED ISSN: 0887-6924

LA English

L58 ANSWER 14 OF 15 BIOSIS COPYRIGHT 1995 BIOSIS

AN 89:352301 BIOSIS

DN BR37:43398

TI **FELINE IMMUNODEFICIENCY VIRUS INFECTION**

AS A MODEL FOR HUMAN AIDS.

AU **PEDERSEN N C; YAMAMOTO J K; ELDER J; NORTH T**

CS UNIV. CALIF., DAVIS, CALIF., USA.

SO 155TH NATIONAL MEETING OF THE AMERICAN ASSOCIATION FOR THE  
ADVANCEMENT OF SCIENCE, SAN FRANCISCO, CALIFORNIA, USA, JANUARY  
14-19, 1989. AAAS PUBL 0 (88-30). 1988. 47. CODEN: AAAPDH

DT Conference

LA English

L58 ANSWER 15 OF 15 COPYRIGHT 1995 DERWENT INFORMATION LTD

AN 94-016008 [02] WPIDS

CR 91-252066 [34]

DNC C94-007621

TI Vaccine contg. inactivated whole **feline**

**immunodeficiency virus** or cells expressing it -

used to protect cats against **FIV** conditions, e.g. alopecia  
and enteritis.

DC B04 C06 D16

IN **PEDERSEN, N C; YAMAMOTO, J K**

PA (REGC) UNIV CALIFORNIA

CYC 1

PI US 5275813 A 940104 (9402)\* 24 pp A61K039-12

ADT US 5275813 A Cont of US 87-89700 870826, CIP of US 90-618030 901116,  
US 91-739014 910731

FDT US 5275813 A CIP of US 5037753

PRAI US 87-89700 870826; US 90-618030 901116; US 91-739014 910731

IC ICM A61K039-12

=> s 125 and adjuvant?

FILE 'BIOSIS'

21790 ADJUVANT?

L59 3 L18 AND ADJUVANT?

FILE 'MEDLINE'

32750 ADJUVANT?

L60 6 L19 AND ADJUVANT?

FILE 'EMBASE'

23901 ADJUVANT?

L61 2 L20 AND ADJUVANT?

FILE 'WPIDS'

4161 ADJUVANT?

L62 5 L21 AND ADJUVANT?

FILE 'VETB'

636 ADJUVANT?

L63 0 L22 AND ADJUVANT?

FILE 'VETU'  
 1626 ADJUVANT?  
 L64 8 L23 AND ADJUVANT?

FILE 'LIFESCI'  
 3531 ADJUVANT?  
 L65 2 L24 AND ADJUVANT?

TOTAL FOR ALL FILES  
 L66 26 L25 AND ADJUVANT?

=> s 166 not 157  
 FILE 'BIOSIS'  
 L67 3 L59 NOT L50

FILE 'MEDLINE'  
 L68 6 L60 NOT L51

FILE 'EMBASE'  
 L69 2 L61 NOT L52

FILE 'WPIDS'  
 L70 5 L62 NOT L53

FILE 'VETB'  
 L71 0 L63 NOT L54

FILE 'VETU'  
 L72 8 L64 NOT L55

FILE 'LIFESCI'  
 L73 2 L65 NOT L56

TOTAL FOR ALL FILES  
 L74 26 L66 NOT L57

=> dup rem 174  
 DUPLICATE IS NOT AVAILABLE IN 'WPIDS'. ANSWERS FROM THESE FILES WILL BE  
 CONSIDERED UNIQUE  
 PROCESSING COMPLETED FOR L74  
 L75 20 DUP REM L74 (6 DUPLICATES REMOVED)

=> d 1-20

L75 ANSWER 1 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD  
 AN 95-60085 VETU  
 TI A neutralizing antibody-inducing peptide of the V3 domain of  
**feline immunodeficiency virus** envelope  
 glycoprotein does not induce protective immunity.  
 AU Lombardi S; Garzelli C; Pistello M; Massi C; Matteucci D;  
 Baldinotti F  
 CS Univ.Pisa  
 LO Pisa, It.  
 SO J.Virol. (68, No. 12, 8374-79, 1994) 4 Fig. 2 Tab. 39 Ref.  
 CODEN: JOVIAM  
 AV Department of Biomedicine, Via San Zeno 37, 56127 Pisa, Italy.  
 (C.G.; 11 authors).

LA English  
 DT Journal  
 FA AB; LA; CT

L75 ANSWER 2 OF 20 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 1

AN 94:436495 BIOSIS

DN 97449495

TI Induction of **feline immunodeficiency virus**-specific cytotoxic T cells in vivo with carrier-free synthetic peptide.

AU Flynn J N; Cannon C A; Beatty J A; Mackett M; Rigby M A; Neil J C; Jarrett O

CS MRC Retrovirus Lab., Dep. Vet. Pathol., University Glasgow, Bearsden, Glasgow G61 1QH, UK

SO Journal of Virology 68 (9). 1994. 5835-5844. ISSN: 0022-538X

LA English

L75 ANSWER 3 OF 20 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 2

AN 94:436529 BIOSIS

DN 97449529

TI Removal of the cleavage site of recombinant **feline immunodeficiency virus** envelope protein facilitates incorporation of the surface glycoprotein in immune-stimulating complexes.

AU Rimmelzwaan G F; Siebelink K H J; Huisman R C; Moss B; Francis M J; Osterhaus A D M E

CS Dep. Virol., Erasmus Univ. Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, NET

SO Journal of General Virology 75 (8). 1994. 2097-2102. ISSN: 0022-1317

LA English

L75 ANSWER 4 OF 20 BIOSIS COPYRIGHT 1995 BIOSIS

AN 95:37625 BIOSIS

DN 98051925

TI Comparison of fibrosarcomas that developed at **vaccination** site and at nonvaccination sites in cats: 239 cases (1991-1992).

AU Hendrick M J; Shofer F S; Goldschmidt M H; Haviland J C; Schelling S H; Engler S J; Gliatto J M

CS Dep. Pathobiol., Sch. Vet. Med., 3800 Spruce St., Univ. Pa., Philadelphia, PA 19104, USA

SO Journal of the American Veterinary Medical Association 205 (10). 1994. 1425-1429. ISSN: 0003-1488

LA English

L75 ANSWER 5 OF 20 MEDLINE

AN 95099285 MEDLINE

TI [**Vaccination** of cats against infection with feline leukemia virus (FeLV): first recombinant **vaccine** and the effect of a pre-existing infection with **feline immunodeficiency virus (FIV)**].

Impfung von Katzen gegen die Infektion mit dem feline Leukamievirus (FeLV): Erster rekombinanter Impfstoff und Einfluss einer vorbestehenden Infektion mit dem feline Immunschwachevirus (FIV).

AU Hofmann-Lehmann R; Aubert A; Wolfensberger C; Cronier J; Lutz H

CS Departement fur Innere Veterinarmedizin, Universitat Zurich.

SO Schweiz Arch Tierheilkd, (1994) 136 (10) 340-51.

Journal code: UE5. ISSN: 0036-7281.

CY Switzerland  
 DT (CLINICAL TRIAL)  
 (CONTROLLED CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA German  
 EM 9503

L75 ANSWER 6 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD

AN 94-60621 VETU

TI The Development of a **Vaccine** against **Feline Immunodeficiency Virus**.

AU Hosie M J

CS Univ.Glasgow

LO Glasgow, U.K.

SO Br.Vet.J. (150, No. 1, 25-39, 1994) 3 Tab. 32 Ref.

CODEN: BVJOA9

AV Department of Veterinary Pathology, University of Glasgow  
 Veterinary School, Bearsden, Glasgow G61 1QH, Scotland.

LA English

DT Journal

FA AB; LA; CT

L75 ANSWER 7 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD

AN 93-60907 VETU

TI Passive Antibody Protection of Cats against **Feline Immunodeficiency Virus** Infection.

AU Hohdatsu T; Pu R; Torres B A; Trujillo S; Gardner M B; Yamamoto J K

LO Davis, Cal.; Gainesville, Fla., USA; Aomori, Jap.

SO J.Virol. (67, No. 4, 2344-48, 1993) 2 Fig. 2 Tab. 20 Ref.

CODEN: JOVIAM

AV Department of Medicine, MS-1A, School of Veterinary Medicine,  
 University of California, Davis, CA 95616, U.S.A.

LA English

DT Journal

FA AB; LA; CT

L75 ANSWER 8 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD

AN 93-60140 VETU

TI Experimental **Vaccine** Protection against Homologous and  
 Heterologous Strains of **Feline Immunodeficiency Virus**.

AU Yamamoto J K; Hohdatsu T; Olmsted R A; Pu R; Louie H; Zochlinski H  
 A

CS Synbiotics

LO Davis; San Diego, Cal., Rockville, Md.; Gainesville, Fla., USA;  
 Aomori-ken, Jap.

SO J.Virol. (67, No. 1, 601-05, 1993) 4 Fig. 2 Tab. 20 Ref.

CODEN: JOVIAM

AV Department of Medicine, MS-1A, School of Veterinary Medicine,  
 University of California, Davis, CA 95616, U.S.A. (10 authors).

LA English

DT Journal

FA AB; LA; CT; MPC

L75 ANSWER 9 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD

AN 93-63815 VETU

TI Reaction Rate in Cats **Vaccinated** with a New Controlled -  
Titer Feline Panleukopenia- Rhinotracheitis- Calicivirus- Chlamydia  
psittaci **vaccine**.  
AU Starr R M  
CS SK-Beecham  
LO West Chester, Pa., USA  
SO Cornell Vet. (83, No. 4, 311-23, 1993) 3 Fig. 2 Tab. 7 Ref.  
CODEN: COVEAZ  
AV Technical Services, SmithKline Beecham Animal Health, Springdale  
Drive, Exton, PA 19341, U.S.A.  
LA English  
DT Journal  
FA AB; LA; CT

L75 ANSWER 10 OF 20 MEDLINE  
AN 92398180 MEDLINE  
TI Immunologic responses in healthy random-source cats fed  
N,N-dimethylglycine-supplemented diets.  
AU Weiss R C  
CS Department of Pathobiology, College of Veterinary Medicine, Auburn  
University, AL 36849.  
SO Am J Vet Res, (1992 May) 53 (5) 829-33.  
Journal code: 40C. ISSN: 0002-9645.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 9212

L75 ANSWER 11 OF 20 MEDLINE  
AN 92398661 MEDLINE  
TI [The effectiveness of paramunization for the control of feline  
coryza].  
Untersuchungen uber die Wirksamkeit der Paramunisierung zur  
Bekampfung des Katzenschnupfens.  
AU Klimentowski S; Kolbl S; Fischer M  
CS Bundesanstalt fur Virusseuchenbekampfung, Haustieren  
Wien-Hetzendorf.  
SO Berl Munch Tierarztl Wochenschr, (1992 Aug 1) 105 (8) 253-9.  
Journal code: 9Q8. ISSN: 0005-9366.  
CY GERMANY: Germany, Federal Republic of  
DT Journal; Article; (JOURNAL ARTICLE)  
LA German  
EM 9212

L75 ANSWER 12 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD  
AN 92-61771 VETU  
TI Factors that can Undermine the Success of Routine  
**Vaccination** Protocols.  
AU McDonald L J  
LO Nanaimo, B.C., Can.  
SO Vet.Med. (87, No. 3, 223-30, 1992) 4 Tab. 30 Ref.  
AV Long Lake Veterinary Hospital, 4508 Wellington Road, Nanaimo,  
British Columbia, Canada V9T 2H3.  
LA English  
DT Journal  
FA AB; LA; CT

- L75 ANSWER 13 OF 20 MEDLINE  
AN 93158180 MEDLINE  
TI Enhancement after feline immunodeficiency  
virus vaccination.  
AU Hosie M J; Osborne R; Reid G; Neil J C; Jarrett O  
CS University of Glasgow, Department of Veterinary Pathology, UK.  
SO Vet Immunol Immunopathol, (1992 Dec) 35 (1-2) 191-7.  
Journal code: XCB. ISSN: 0165-2427.  
CY Netherlands  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 9305
- L75 ANSWER 14 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD  
AN 92-60662 VETU  
TI Vaccination of Cats Experimentally Infected with  
Feline Immunodeficiency Virus, Using a  
Recombinant Feline Leukemia Virus Vaccine.  
AU Lehmann R; Franchini M; Aubert A; Wolfensberger C; Cronier J; Lutz  
H  
LO Zurich, Switz.; Carros, Fr.  
SO J.Am.Vet.Med.Assoc. (199, No. 10, 1446-52, 1991) 5 Fig. 29 Ref.  
CODEN: JAVMA4  
AV Department of Medicine, School of Veterinary Medicine, University  
of Zurich, Winterhurerstr 260, CH-8057, Zurich, Switzerland.  
(H.L.).  
LA English  
DT Journal  
FA AB; LA; CT
- L75 ANSWER 15 OF 20 VETU COPYRIGHT 1995 DERWENT INFORMATION LTD  
AN 92-60661 VETU  
TI Toward Vaccination Against Feline Leukemia Virus and  
Feline Immunodeficiency Virus  
Infections.  
AU Osterhaus A D M E; Weijer K; Siebelink K H J; Rimmelzwaan G F;  
Bosch M L  
LO Bilthoven; Amsterdam, Neth.  
SO J.Am.Vet.Med.Assoc. (199, No. 10, 1443-46, 1991) 24 Ref.  
CODEN: JAVMA4  
AV Laboratory of Immunobiology, National Institute of Public Health  
and Environmental Protection, Bilthoven, The Netherlands.  
LA English  
DT Journal  
FA AB; LA; CT
- L75 ANSWER 16 OF 20 COPYRIGHT 1995 DERWENT INFORMATION LTD  
AN 94-303029 [37] WPIDS  
DNC C94-138229  
TI Polypeptide fragment of feline immunodeficiency  
virus (FIV) surface protein - useful in  
vaccine, capable of neutralising antibodies against  
FIV.  
DC B04 C06 D16  
IN DE, RONDE A; EGBERINK, H F; HORZINEK, M C; KELDERMANS, C E J M



PA (ALKU) AKZO NOBEL NV  
 CYC 19  
 PI WO 9420622 A1 940915 (9437)\* 49 pp C12N015-49  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
 W: CA JP US  
 ADT WO 9420622 A1 WO 94-EP812 940310  
 PRAI EP 93-200704 930311  
 IC ICM C12N015-49  
 ICS A61K039-21; C07K007-06; C07K007-08; C07K015-00; C12P021-08  
  
 L75 ANSWER 17 OF 20 COPYRIGHT 1995 DERWENT INFORMATION LTD  
 AN 93-303135 [38] WPIDS  
 DNC C93-134980  
 TI New T4 immune stimulating factor derived from thymus - used for  
 treating neoplastic disease or infection or as **vaccine**  
**adjuvant.**  
 DC B04 C06 D16  
 IN BEARDSLEY, T R  
 PA (BEAR-I) BEARDSLEY T R  
 CYC 21  
 PI WO 9317700 A1 930916 (9338)\* EN 16 pp A61K037-02  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
 W: AU CA JP US  
 AU 9339160 A 931005 (9405) A61K037-02  
 EP 630257 A1 941228 (9505) EN A61K037-02  
 R: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  
 ADT WO 9317700 A1 WO 93-US2056 930309; AU 9339160 A AU 93-39160 930309;  
 EP 630257 A1 EP 93-908285 930309, WO 93-US2056 930309  
 FDT AU 9339160 A Based on WO 9317700; EP 630257 A1 Based on WO 9317700  
 PRAI US 92-850586 920313  
 IC ICM A61K037-02  
 ICS A61K035-26; C07K015-00  
  
 L75 ANSWER 18 OF 20 COPYRIGHT 1995 DERWENT INFORMATION LTD  
 AN 93-243213 [30] WPIDS  
 DNC C93-108435  
 TI Production of protein- or peptide-contg. agent with enhanced  
 immunogenicity - by treating with hypericin or its deriv., useful  
 for treating and preventing HIV, HTLV, FIV etc..  
 DC B04 C06 D16  
 IN LAVIE, G; MERUELO, D  
 PA (UYNV) UNIV NEW YORK STATE  
 CYC 19  
 PI WO 9314197 A1 930722 (9330)\* EN 40 pp C12N007-06  
 RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
 W: AU CA JP  
 AU 9334745 A 930803 (9348) C12N007-06  
 ADT WO 9314197 A1 WO 93-US364 930119; AU 9334745 A AU 93-34745 930119,  
 WO 93-US364 930119  
 FDT AU 9334745 A Based on WO 9314197  
 PRAI US 92-821945 920116  
 IC ICM C12N007-06  
 ICS A61K039-12; C12N001-36  
  
 L75 ANSWER 19 OF 20 COPYRIGHT 1995 DERWENT INFORMATION LTD  
 AN 93-167398 [20] WPIDS  
 DNC C93-074615

TI Enhancing immunogenicity of viral envelope glycoprotein - by  
co-administration of viral envelope glycoprotein itself, and an  
oligopeptide derive..  
DC B04 D16  
IN GIRARD, M  
PA (INSP) INST PASTEUR  
CYC 19  
PI WO 9308836 A1 930513 (9320)\* EN 107 pp A61K039-21  
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE  
W: AU CA JP  
AU 9228003 A 930607 (9338) A61K039-21  
EP 613378 A1 940907 (9434) EN A61K039-21  
R: AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE  
ADT WO 9308836 A1 WO 92-EP2459 921028; AU 9228003 A AU 92-28003 921028;  
EP 613378 A1 EP 92-922431 921028, WO 92-EP2459 921028  
FDT AU 9228003 A Based on WO 9308836; EP 613378 A1 Based on WO 9308836  
PRAI US 91-782154 911028; US 91-782241 911028; US 91-782252 911028  
IC ICM A61K039-21

L75 ANSWER 20 OF 20 COPYRIGHT 1995 DERWENT INFORMATION LTD

AN 93-045484 [05] WPIDS

DNC C93-020586

TI New interleukin-2 dependent feline lymphoid cell line - produce  
**feline immunodeficiency virus** for use in  
**vaccines** for protection against infection in cats.

DC B04 C06 D16

IN YAMAMOTO, J K

PA (REGC) UNIV CALIFORNIA

CYC 17

PI WO 9301278 A1 930121 (9305)\* EN 59 pp C12N005-10

RW: AT BE CH DE DK ES FR GB GR IT LU MC NL SE

W: AU CA JP

AU 9222998 A 930211 (9321) C12N005-10

ADT WO 9301278 A1 WO 92-US5571 920701; AU 9222998 A AU 92-22998 920701

FDT AU 9222998 A Based on WO 9301278

PRAI US 91-726061 910705

IC ICM C12N005-10

ICS A61K035-76; C12N007-00

=> s protect?(w)(cat or kitten or feline) and against(w)l17

FILE 'BIOSIS'

128628 PROTECT?

90161 CAT

1675 KITTEN

6853 FELINE

4 PROTECT?(W)(CAT OR KITTEN OR FELINE)

221634 AGAINST

15 AGAINST(W)L10

L76 0 PROTECT?(W)(CAT OR KITTEN OR FELINE) AND AGAINST(W)L10

FILE 'MEDLINE'

111685 PROTECT?

43718 CAT

860 KITTEN

5785 FELINE

2 PROTECT?(W)(CAT OR KITTEN OR FELINE)

199000 AGAINST

12 AGAINST(W) L11  
 L77 0 PROTECT?(W) (CAT OR KITTEN OR FELINE) AND AGAINST(W) L11

## FILE 'EMBASE'

107008 PROTECT?  
 59298 CAT  
 826 KITTEN  
 4080 FELINE  
 5 PROTECT?(W) (CAT OR KITTEN OR FELINE)  
 187286 AGAINST  
 13 AGAINST(W) L12  
 L78 0 PROTECT?(W) (CAT OR KITTEN OR FELINE) AND AGAINST(W) L12

## FILE 'WPIDS'

265598 PROTECT?  
 2222 CAT  
 10 KITTEN  
 301 FELINE  
 7 PROTECT?(W) (CAT OR KITTEN OR FELINE)  
 365463 AGAINST  
 3 AGAINST(W) L13  
 L79 1 PROTECT?(W) (CAT OR KITTEN OR FELINE) AND AGAINST(W) L13

## FILE 'VETB'

491 PROTECT?  
 2415 CAT  
 18 KITTEN  
 455 FELINE  
 0 PROTECT?(W) (CAT OR KITTEN OR FELINE)  
 4416 AGAINST  
 0 AGAINST(W) L14  
 L80 0 PROTECT?(W) (CAT OR KITTEN OR FELINE) AND AGAINST(W) L14

## FILE 'VETU'

4124 PROTECT?  
 2470 CAT  
 48 KITTEN  
 874 FELINE  
 0 PROTECT?(W) (CAT OR KITTEN OR FELINE)  
 9688 AGAINST  
 12 AGAINST(W) L15  
 L81 0 PROTECT?(W) (CAT OR KITTEN OR FELINE) AND AGAINST(W) L15

## FILE 'LIFESCI'

32959 PROTECT?  
 11555 CAT  
 250 KITTEN  
 1978 FELINE  
 0 PROTECT?(W) (CAT OR KITTEN OR FELINE)  
 68625 AGAINST  
 11 AGAINST(W) L16  
 L82 0 PROTECT?(W) (CAT OR KITTEN OR FELINE) AND AGAINST(W) L16

## TOTAL FOR ALL FILES

L83 1 PROTECT?(W) (CAT OR KITTEN OR FELINE) AND AGAINST(W) L17

=> d

L83 ANSWER 1 OF 1 COPYRIGHT 1995 DERWENT INFORMATION LTD  
 AN 94-016008 [02] WPIDS  
 CR 91-252066 [34]  
 DNC C94-007621  
 TI Vaccine contg. inactivated whole feline immunodeficiency virus or  
 cells expressing it - used to protect cats against  
 FIV conditions, e.g. alopecia and enteritis.  
 DC B04 C06 D16  
 IN PEDERSEN, N C; YAMAMOTO, J K  
 PA (REGC) UNIV CALIFORNIA  
 CYC 1  
 PI US 5275813 A 940104 (9402)\* 24 pp A61K039-12  
 ADT US 5275813 A Cont of US 87-89700 870826, CIP of US 90-618030 901116,  
 US 91-739014 910731  
 FDT US 5275813 A CIP of US 5037753  
 PRAI US 87-89700 870826; US 90-618030 901116; US 91-739014 910731  
 IC ICM A61K039-12

=> s immunogen and immune response and l17

FILE 'BIOSIS'

2701 IMMUNOGEN  
 126475 IMMUNE  
 481156 RESPONSE  
 35289 IMMUNE RESPONSE  
 (IMMUNE(W)RESPONSE)

L84 1 IMMUNOGEN AND IMMUNE RESPONSE AND L10

FILE 'MEDLINE'

2214 IMMUNOGEN  
 145290 IMMUNE  
 483302 RESPONSE  
 23717 IMMUNE RESPONSE  
 (IMMUNE(W)RESPONSE)

L85 1 IMMUNOGEN AND IMMUNE RESPONSE AND L11

FILE 'EMBASE'

2207 IMMUNOGEN  
 142052 "IMMUNE"  
 507795 "RESPONSE"  
 39382 IMMUNE RESPONSE  
 ("IMMUNE"(W)"RESPONSE")

L86 1 IMMUNOGEN AND IMMUNE RESPONSE AND L12

FILE 'WPIDS'

604 IMMUNOGEN  
 9258 IMMUNE  
 131578 RESPONSE  
 1233 IMMUNE RESPONSE  
 (IMMUNE(W)RESPONSE)

L87 1 IMMUNOGEN AND IMMUNE RESPONSE AND L13

FILE 'VETB'

8 IMMUNOGEN  
 589 IMMUNE  
 3348 RESPONSE  
 298 IMMUNE RESPONSE

(IMMUNE(W) RESPONSE)  
 L88 0 IMMUNOGEN AND IMMUNE RESPONSE AND L14

FILE 'VETU'

107 IMMUNOGEN  
 2335 IMMUNE  
 8909 RESPONSE  
 1344 IMMUNE RESPONSE  
 (IMMUNE(W) RESPONSE)

L89 0 IMMUNOGEN AND IMMUNE RESPONSE AND L15

FILE 'LIFESCI'

944 IMMUNOGEN  
 43168 "IMMUNE"  
 109417 "RESPONSE"  
 15386 IMMUNE RESPONSE  
 ("IMMUNE"(W) "RESPONSE")

L90 3 IMMUNOGEN AND IMMUNE RESPONSE AND L16

TOTAL FOR ALL FILES

L91 7 IMMUNOGEN AND IMMUNE RESPONSE AND L17

=> dup rem 191

DUPLICATE IS NOT AVAILABLE IN 'WPIDS'. ANSWERS FROM THESE FILES WILL BE  
 CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L91

L92 4 DUP REM L91 (3 DUPLICATES REMOVED)

=> d 1-4

L92 ANSWER 1 OF 4 BIOSIS COPYRIGHT 1995 BIOSIS DUPLICATE 1

AN 94:436495 BIOSIS

DN 97449495

TI Induction of **feline immunodeficiency**  
**virus**-specific cytotoxic T cells in vivo with carrier-free  
 synthetic peptide.

AU Flynn J N; Cannon C A; Beatty J A; Mackett M; Rigby M A; Neil J C;  
 Jarrett O

CS MRC Retrovirus Lab., Dep. Vet. Pathol., University Glasgow, Bearsden,  
 Glasgow G61 1QH, UK

SO Journal of Virology 68 (9). 1994. 5835-5844. ISSN: 0022-538X

LA English

L92 ANSWER 2 OF 4 LIFESCI COPYRIGHT 1995 CSA

AN 94:20931 LIFESCI

TI Methods and compositions for vaccinating against **feline**  
**immunodeficiency virus**

AU Yamamoto, J.K.; Pedersen, N.C.

CS Regents Univ. California, Oakland, CA (USA)

SO (1994) . US Patent 5,275,813; US Cl. 424/89; Int. Cl. A61K 39/12..

DT Patent

FS V; W2

LA English

L92 ANSWER 3 OF 4 LIFESCI COPYRIGHT 1995 CSA

AN 91:4174 LIFESCI

TI Progressive immune dysfunction in cats experimentally infected with

**feline immunodeficiency virus.**

AU Torten, M.; Franchini, M.; Barlough, J.E.; George, J.W.; Mozes, E.;  
 Lutz, H.; Pedersen, N.C.  
 CS Dep. Med., Sch. Vet. Med., Univ. California, Davis, CA 95616, USA  
 SO J. VIROL., (1991) vol. 65, no. 5, pp. 2225-2230.  
 DT Journal  
 FS V; F  
 LA English  
 SL English

L92 ANSWER 4 OF 4 COPYRIGHT 1995 DERWENT INFORMATION LTD

AN 93-045484 [05] WPIDS

DNC C93-020586

TI New interleukin-2 dependent feline lymphoid cell line - produce  
**feline immunodeficiency virus** for use in  
 vaccines for protection against infection in cats.

DC B04 C06 D16

IN YAMAMOTO, J K

PA (REGC) UNIV CALIFORNIA

CYC 17

PI WO 9301278 A1 930121 (9305)\* EN 59 pp C12N005-10

RW: AT BE CH DE DK ES FR GB GR IT LU MC NL SE

W: AU CA JP

AU 9222998 A 930211 (9321) C12N005-10

ADT WO 9301278 A1 WO 92-US5571 920701; AU 9222998 A AU 92-22998 920701

FDT AU 9222998 A Based on WO 9301278

PRAI US 91-726061 910705

IC ICM C12N005-10

ICS A61K035-76; C12N007-00

=> fil ca

FILE 'CA' ENTERED AT 11:39:58 ON 21 MAR 95

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 1995 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1967 - 18 Mar 1995 (950318/ED) VOL 122 ISS 12

To help control your online searching costs, consider using the  
 HCA File when using the FSEARCH command or when conducting  
 SmartSELECT searches with large numbers of terms.

CAPLUS IS NOW ONLINE!

436/501, 515, 518, 530, 548 [IMAGE AVAILABLE]

56. 5,264,356, Nov. 23, 1993, Regulating retroviral replication, infection, and pathogenesis; Larry R. Rohrschneider, 435/236, 235.1, 240.1, 240.2; 514/315, 413, 425 [IMAGE AVAILABLE]

57. 5,256,767, Oct. 26, 1993, Retroviral antigens; Jonas Salk, et al., 424/208.1, 160.1; 435/236, 238; 530/350, 389.4, 395 [IMAGE AVAILABLE]

58. 5,256,677, Oct. 26, 1993, Retroviral protease inhibiting compounds; Hing L. Sham, et al., 514/351, 352, 357, 616; 546/300, 301, 309, 312, 331, 332, 335, 337 [IMAGE AVAILABLE]

59. 5,256,642, Oct. 26, 1993, Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof; Douglas T. Fearon, et al., 514/8; 424/94.63, 94.64; 435/215, 216; 514/2; 530/350 [IMAGE AVAILABLE]

60. 5,254,678, Oct. 19, 1993, Ribozymes; James P. Haseloff, et al., 536/23.2; 435/172.3, 240.1, 252.3, 320.1; 536/23.1 [IMAGE AVAILABLE]

61. 5,254,339, Oct. 19, 1993, Process for preparing immune complexes; Bror Morein, 424/191.1, 193.1, 195.11, 196.11, 197.11; 514/2, 8 [IMAGE AVAILABLE]

62. 5,252,348, Oct. 12, 1993, Artificial viral envelopes; Hans Schreier, et al., 424/450; 264/4.1; 424/196.11, 208.1, 211.1, 812; 436/829 [IMAGE AVAILABLE]

63. 5,242,820, Sep. 7, 1993, Pathogenic mycoplasma; Shyh-Ching Lo, 435/240.2, 5, 872 [IMAGE AVAILABLE]

64. 5,242,812, Sep. 7, 1993, Method for production and purification of hepatitis B \*\*vaccine\*\*; Zeev Even-Chen, 435/70.3; 424/227.1; 435/69.3; 530/395, 412, 414, 415, 416, 417, 806; 935/65 [IMAGE AVAILABLE]

65. 5,236,835, Aug. 17, 1993, Electro insertion of proteins into red cell membranes; Youssef Mouneimne, et al., 435/173.6; 514/8 [IMAGE AVAILABLE]

66. 5,223,409, Jun. 29, 1993, Directed evolution of novel binding proteins; Robert C. Ladner, et al., 435/69.7, 5, 69.1, 172.3, 252.3, 320.1; 530/387.3, 387.5 [IMAGE AVAILABLE]

67. 5,221,778, Jun. 22, 1993, Multiplex gene regulation; Guerard W. Byrne, et al., 800/2; 424/231.1; 435/172.3, 317.1, 948; 800/DIG.1, DIG.4; 935/111 [IMAGE AVAILABLE]

68. 5,215,917, Jun. 1, 1993, Nucleotide sequence encoding the Toxoplasma gondii P22 gene; Fausto G. De Araujo, et al., 435/252.33, 69.3, 172.3, 235.1, 252.3, 320.1; 530/350; 536/23.2, 23.4, 23.5, 23.7 [IMAGE AVAILABLE]

69. 5,215,745, Jun. 1, 1993, Method for treating viral diseases with attenuated virus; Laszlo K. Csatory, et al., 424/281.1 [IMAGE AVAILABLE]

70. 5,208,221, May 4, 1993, Antiviral (phosphonmethoxy) methoxy purine/pyrimidine derivatives; Choung U. Kim, et al., 514/81, 86, 89; 544/243, 244; 546/23 [IMAGE AVAILABLE]

71. 5,206,244, Apr. 27, 1993, Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines; Robert Zahler, et al., 514/262, 81, 86, 258, 261, 264, 269, 272, 274; 544/243, 244, 254, 264, 265, 276, 277, 310, 317 [IMAGE AVAILABLE]

72. 5,198,342, Mar. 30, 1993, DNA encoding IgA Fc receptors; Charles R. Maliszewski, 435/69.1, 252.3, 320.1; 530/350, 861; 536/23.5 [IMAGE AVAILABLE]

73. 5,192,553, Mar. 9, 1993, Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use; Edward A. Boyse, et al., 424/529; 435/2, 172.1, 172.3, 240.2, 240.26 [IMAGE AVAILABLE]

74. 5,190,873, Mar. 2, 1993, Hybrid tryptophan aporepressor containing ligand binding sites; Waldemar Lernhardt, et al., 435/177, 69.1, 69.7; 530/350, 812; 930/250 [IMAGE AVAILABLE]

75. 5,189,014, Feb. 23, 1993, Method of treating cellular Fc receptor mediated hypersensitivity immune disorders; Fred M. Cowan, Jr., 514/2 [IMAGE AVAILABLE]
76. 5,188,897, Feb. 23, 1993, Encapsulated 2',5'-phosphorothioate oligoadenylates; Robert J. Suhadolnik, et al., 428/402.2; 424/450; 514/44; 536/25.5, 25.6 [IMAGE AVAILABLE]
77. 5,185,459, Feb. 9, 1993, Bis protected (hydroxymethyl)cyclobutanols; William A. Slusarchyk, et al., 556/449, 436; 560/106, 193, 231; 568/660 [IMAGE AVAILABLE]
78. 5,182,107, Jan. 26, 1993, Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates; Phillip M. Friden, 424/179.1, 94.1, 143.1, 178.1; 514/21; 530/387.3, 388.22, 391.1, 391.7, 391.9, 399 [IMAGE AVAILABLE]
79. 5,176,921, Jan. 5, 1993, Method of blood component decontamination by glucose addition; Gary P. Wieseahn, et al., 424/176.1, 85.1, 85.2, 85.4, 93.72, 93.73, 530, 532; 435/2; 514/2, 8; 530/383, 384, 390.1 [IMAGE AVAILABLE]
80. 5,175,292, Dec. 29, 1992, Intermediates for the preparation of dideoxycarbocyclic nucleosides; Robert Vince, et al., 544/323, 326 [IMAGE AVAILABLE]
81. 5,174,993, Dec. 29, 1992, Recombinant avipox virus and immunological use thereof; Enzo Paoletti, 424/199.1, 207.1, 210.1, 214.1, 222.1, 224.1, 231.1, 232.1; 435/235.1, 320.1; 935/32, 57, 65 [IMAGE AVAILABLE]
82. 5,171,662, Dec. 15, 1992, Method of detecting \*\*HIV\*\* protease activity; Satish K. Sharma, 435/5, 7.1, 7.92, 23, 24, 974 [IMAGE AVAILABLE]
83. 5,169,784, Dec. 8, 1992, Baculovirus dual promoter expression vector; Max D. Summers, et al., 435/320.1; 935/32 [IMAGE AVAILABLE]
84. 5,166,057, Nov. 24, 1992, Recombinant negative strand RNA virus expression-systems; Peter Palese, et al., 435/69.1, 172.3, 194, 235.1, 320.1; 935/32, 34, 57 [IMAGE AVAILABLE]
85. 5,166,050, Nov. 24, 1992, Monoclonal antibodies and peptides useful in treating and diagnosing \*\*HIV\*\* infections; Mary K. Shriver, et al., 435/5; 424/139.1, 148.1, 188.1, 208.1; 435/70.21, 172.2, 240.27; 530/388.1, 388.35, 389.4, 864, 868 [IMAGE AVAILABLE]
86. 5,164,520, Nov. 17, 1992, Intermediates for purinyl and pyrimidinyl tetrahydrofurans; Robert Zahler, et al., 549/475, 502 [IMAGE AVAILABLE]
87. 5,164,300, Nov. 17, 1992, Method for determining activity of retroviral protease; Garland R. Marshall, et al., 435/23; 252/301.16; 435/24; 436/63, 172, 800, 810, 815; 530/329 [IMAGE AVAILABLE]
88. 5,154,924, Oct. 13, 1992, Transferrin receptor specific antibody-neuropharmaceutical agent conjugates; Phillip Friden, 424/179.1, 85.2, 94.3, 152.1, 178.1, 181.1; 435/188; 530/302, 311, 351, 370, 388.22, 391.1, 391.3, 391.5, 391.7, 391.9, 399 [IMAGE AVAILABLE]
89. 5,151,438, Sep. 29, 1992, Retroviral protease inhibiting compounds; Hing L. Sham, et al., 514/357, 351, 352, 616; 546/300, 301, 309, 312, 331, 332, 335, 337; 564/342, 372 [IMAGE AVAILABLE]
90. 5,149,785, Sep. 22, 1992, Proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retroviruses; Harvey I. Cantor, et al., 530/350, 397; 930/25; 935/36 [IMAGE AVAILABLE]
91. 5,145,960, Sep. 8, 1992, Pyrimidinyl tetrahydrofurans; Robert Zahler, et al., 544/310, 244, 313, 314, 317 [IMAGE AVAILABLE]
92. 5,145,839, Sep. 8, 1992, Pharmaceutical composition and method of use; Mirko Beljanski, 514/27, 456; 536/4.1, 18.1 [IMAGE AVAILABLE]
93. 5,142,056, Aug. 25, 1992, Retroviral protease inhibiting compounds; Dale J. Kempe, et al., 546/265; 544/58.4, 131, 158, 359, 365, 367, 383; 546/245, 264, 280, 328, 334, 335; 548/204, 305.7, 312.7, 338.1, 341.5, 376.1, 532; 549/453, 548, 553, 562; 560/25, 26 [IMAGE AVAILABLE]



94. 5,137,876, Aug. 11, 1992, Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same; Malcolm MacCoss, et al., 514/23, 43; 536/18.4, 18.7, 29.2, 55, 117, 121 [IMAGE AVAILABLE]
95. 5,130,462, Jul. 14, 1992, Cyclobutane derivatives; William A. Slusarchyk, et al., 558/58; 556/428, 482; 558/44, 57; 560/81, 105, 106, 123, 266; 568/660, 661, 662, 663 [IMAGE AVAILABLE]
96. 5,126,345, Jun. 30, 1992, Bis (hydroxymethyl) cyclobutyl triazolopyrimidines; William A. Slusarchyk, et al., 514/254, 81, 86, 261, 269; 544/243, 254, 265, 277, 309, 317, 323; 556/443; 558/57; 560/8, 123; 568/670, 839 [IMAGE AVAILABLE]
97. 5,124,148, Jun. 23, 1992, Method for treating viral diseases with attenuated virus; Laszlo K. Csatory, et al., 424/281.1 [IMAGE AVAILABLE]
98. 5,122,517, Jun. 16, 1992, Antiviral combination comprising nucleoside analogs; Robert Vince, et al., 514/50, 45, 46, 49, 258, 262, 265, 885 [IMAGE AVAILABLE]
99. 5,120,843, Jun. 9, 1992, Pharmaceutically active amines; John M. McCall, et al., 544/123; 536/31; 540/450, 480, 481, 483, 542, 596, 598, 603, 608; 544/53, 54, 55, 57, 58.1, 58.4, 58.5, 58.6, 60, 62, 69, 82, 83, 96, 113, 121, 122, 182, 194, 195, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 216, 217, 218, 219, 229, 232, 238, 243, 295, 316, 317, 318, 319, 320, 321, 324, 327, 328, 331, 333, 337, 357, 360, 364, 365, 366, 368, 370, 372, 373, 376, 377, 405, 406; 546/14, 22, 197, 210, 227; 548/112, 305.1, 311.7, 406, 413, 526, 535 [IMAGE AVAILABLE]
100. 5,118,673, Jun. 2, 1992, Uses of aloe products; Robert H. Carpenter, et al., 514/54, 935 [IMAGE AVAILABLE]
101. 5,118,602, Jun. 2, 1992, \*\*Feline\*\* T-lymphotropic lentivirus assay; Niels C. Pedersen, et al., 435/5, 7.92; 436/518 [IMAGE AVAILABLE]
102. 5,115,096, May 19, 1992, Amphiregulin: a bifunctional growth modulating glycoprotein; Mohammed Shoyab, et al., 530/322, 324 [IMAGE AVAILABLE]
103. 5,112,756, May 12, 1992, Continuous production of bovine Maedi-Visna-like viral antigens in Cf2Th cells; Alain M. P. Bouillant, et al., 435/235.1, 239, 240.1, 240.2, 240.25, 948 [IMAGE AVAILABLE]
104. 5,106,965, Apr. 21, 1992, Detection of human adenovirus; Norman J. Pieniazek, et al., 536/23.72; 435/5; 530/350; 536/24.3, 24.32 [IMAGE AVAILABLE]
105. 5,106,616, Apr. 21, 1992, Administration of acemannan; Bill H. McAnalley, et al., 424/85.2; 514/54, 885 [IMAGE AVAILABLE]
106. 5,086,002, Feb. 4, 1992, Erythrocyte agglutination assay; Carmel J. Hillyard, et al., 436/540; 422/61; 435/7.25; 436/501, 519; 530/387.3, 388.7, 389.1, 866 [IMAGE AVAILABLE]
107. 5,079,342, Jan. 7, 1992, Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (\*\*HIV\*\*-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits; Marc Alizon, et al., 530/324; 435/5, 974; 530/326, 327, 328, 329 [IMAGE AVAILABLE]
108. 5,077,284, Dec. 31, 1991, Use of dehydroepiandrosterone to improve immune response; Roger M. Loria, et al., 514/171; 424/434, 451, 464; 514/169, 170, 885, 937 [IMAGE AVAILABLE]
109. 5,071,878, Dec. 10, 1991, Use of methylsulfonylmethane to enhance diet of an animal; Robert J. Herschler, 514/711 [IMAGE AVAILABLE]
110. 5,064,946, Nov. 12, 1991, Therapeutic nucleosides; Sammy R. Shaver, et al., 536/28.2, 27.14 [IMAGE AVAILABLE]
111. 5,059,690, Oct. 22, 1991, Purinyl tetrahydrofurans; Robert Zahler, et al., 544/276, 243, 244, 265, 277, 313, 314, 317; 549/476 [IMAGE AVAILABLE]
112. 5,051,407, Sep. 24, 1991, Methods for treating viruses in patients

by administering 2-hydroxymethylene-3,4,5-trihydropiperidines; Horst Boshagen, et al., 514/24, 315, 316, 319, 325, 326, 328 [IMAGE AVAILABLE]

113. 5,041,385, Aug. 20, 1991, Vector expressing fusion proteins and particles; Alan J. Kingsman, et al., 435/320.1; 424/192.1, 210.1; 435/69.3, 69.7, 91.41, 170, 171, 172.1, 172.3, 235.1, 240.2, 252.3, 254.21; 436/543; 536/23.4, 23.7; 935/9, 12, 22, 28, 47, 59, 60, 69 [IMAGE AVAILABLE]

114. 5,041,379, Aug. 20, 1991, Heliothis expression systems; Malcolm J. Fraser, et al., 435/235.1, 69.1, 70.1, 172.3, 240.2, 320.1; 536/23.2, 23.6, 23.72; 935/3, 6, 9, 22, 33, 34, 47, 48, 59, 60, 61, 66, 70 [IMAGE AVAILABLE]

115. 5,039,522, Aug. 13, 1991, Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen; Alexander R. Neurath, 424/194.1, 186.1, 187.1, 190.1, 196.11, 210.1, 216.1, 227.1, 244.1, 245.1; 530/404, 405, 406 [IMAGE AVAILABLE]

116. 5,037,753, Aug. 6, 1991, \*\*Feline\*\* t-lymphotropic lentivirus; Niels C. Pedersen, et al., 435/235.1; 424/208.1; 435/5, 948; 530/388.35 [IMAGE AVAILABLE]

117. 5,037,649, Aug. 6, 1991, Method for treatment of \*\*HIV\*\*-infected patients; Joseph P. Balint, Jr., et al., 424/140.1; 210/263, 656, 691; 424/810; 436/523, 527; 502/403; 530/413; 604/5 [IMAGE AVAILABLE]

118. 5,030,200, Jul. 9, 1991, Method for eradicating infectious biological contaminants in body tissues; Millard M. Judy, et al., 604/5; 424/529 [IMAGE AVAILABLE]

119. 5,026,688, Jun. 25, 1991, Novel AZT analogs; Krishna Agrawal, 514/50, 885; 536/28.2 [IMAGE AVAILABLE]

120. 5,019,495, May 28, 1991, Tissue culture antiviral processes and compositions; Edward Shanbrom, 435/1, 2, 235.1, 240.1, 240.2 [IMAGE AVAILABLE]

121. 5,019,382, May 28, 1991, Treatment of immuno-resistant disease with low-dose interferon; Joseph M. Cummins, Jr., 424/85.4, 85.6, 85.7 [IMAGE AVAILABLE]

122. 5,017,687, May 21, 1991, Peptides for the detection of HTLV-1 infection; Anders Vahlne, et al., 424/187.1, 207.1; 435/5; 514/12; 530/324, 325, 326 [IMAGE AVAILABLE]

123. 5,013,663, May 7, 1991, Canine corona virus \*\*vaccine\*\*; William M. Acree, et al., 424/221.1, 818; 435/23, 235.1, 236, 237 [IMAGE AVAILABLE]

124. 5,011,910, Apr. 30, 1991, Reagent and method for determining activity of retroviral protease; Garland R. Marshall, et al., 530/329; 435/23; 530/324, 327 [IMAGE AVAILABLE]

125. 5,008,373, Apr. 16, 1991, Fusion proteins and particles; Alan J. Kingsman, et al., 530/350; 435/69.7, 170, 171, 172.3, 233, 240.2, 252.3, 254.2, 254.21, 320.1; 530/351, 412; 536/23.4; 935/10, 12, 22, 59, 66 [IMAGE AVAILABLE]

126. 5,004,681, Apr. 2, 1991, Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood; Edward A. Boyse, et al., 435/2; 424/529 [IMAGE AVAILABLE]

127. 4,999,421, Mar. 12, 1991, HTLV-I anti-sense RNA and encoded proteins; Terence K. Brunck, et al., 530/350; 435/6; 514/25; 530/806 [IMAGE AVAILABLE]

128. 4,990,498, Feb. 5, 1991, 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof; Robert J. Suhadolnik, 514/47, 48; 536/25.5, 25.6, 26.21, 26.26, 27.7 [IMAGE AVAILABLE]

129. 4,983,387, Jan. 8, 1991, \*\*HIV\*\* related peptides, immunogenic antigens, and use therefor as subunit \*\*vaccine\*\* for \*\*AIDS\*\* virus; Allan Goldstein, et al., 424/188.1, 196.11, 208.1; 530/324, 325, 326, 345, 388.23, 389.2, 403, 806, 807; 930/221 [IMAGE AVAILABLE]

130. 4,980,462, Dec. 25, 1990, Antiviral agents; Karl-Anders Karlsson, et al., 536/53; 424/520; 514/25, 53, 613, 625; 536/4.1, 54, 55, 115, 116,

118, 120, 122 [IMAGE AVAILABLE]

131. 4,973,605, Nov. 27, 1990, Use of methylsulfonylmethane to relieve pain and relieve pain and nocturnal cramps and to reduce stress-induced deaths in animals; Robert J. Herschler, 514/708 [IMAGE AVAILABLE]

132. 4,970,071, Nov. 13, 1990, Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms; John McMichael, 424/198.1, 277.1, 282.1, 520 [IMAGE AVAILABLE]

133. 4,966,753, Oct. 30, 1990, Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms; John McMichael, 424/198.1, 277.1, 282.1, 520; 514/8 [IMAGE AVAILABLE]

134. 4,965,069, Oct. 23, 1990, Oxidized viruses or viral antigens and utilization for diagnostic prophylactic and/or therapeutic applications; Gerard A. Quash, et al., 424/208.1, 204.1, 209.1, 211.1, 212.1, 215.1, 216.1, 219.1, 225.1, 230.1, 231.1; 435/238 [IMAGE AVAILABLE]

135. 4,962,091, Oct. 9, 1990, Controlled release of macromolecular polypeptides; Deborah A. Eppstein, et al., 424/85.2, 85.1, 85.4, 85.6, 130.1, 178.1, 184.1, 193.1, 499; 514/2, 21, 964 [IMAGE AVAILABLE]

136. 4,952,499, Aug. 28, 1990, Genes and their encoded proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retroviruses; Harvey I. Cantor, et al., 435/69.1, 172.1, 172.3, 240.2, 252.33, 320.1; 536/23.52, 23.72, 24.1 [IMAGE AVAILABLE]

137. 4,950,758, Aug. 21, 1990, Optically-active isomers of dideoxycarbocyclic nucleosides; Robert Vince, et al., 544/276, 254, 264, 265, 267, 277 [IMAGE AVAILABLE]

138. 4,940,705, Jul. 10, 1990, N-substituted derivatives of 1-desoxynojirimycin and 1-desoxymannonojirimycin and pharmaceutical use; Horst Boshagen, et al., 514/227.8, 235.5, 235.8, 255, 256, 305, 314, 315, 316, 318, 321, 326, 328; 544/58.4, 58.6, 122, 130, 238, 245, 335, 360; 546/133, 165, 173, 188, 193, 194, 197, 201 [IMAGE AVAILABLE]

139. 4,935,372, Jun. 19, 1990, Art nucleotide segments, vectors, cell lines methods of preparation and use; Wei C. Goh, 435/317.1, 69.1, 69.3, 172.3, 240.2, 320.1; 536/23.72, 24.1; 935/22, 70, 71 [IMAGE AVAILABLE]

140. 4,931,559, Jun. 5, 1990, Optically-active isomers of dideoxycarbocyclic nucleosides; Robert Vince, et al., 544/276, 254, 265, 277 [IMAGE AVAILABLE]

141. 4,924,624, May 15, 1990, 2',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof; Robert J. Suhadolnik, et al., 47/58; 536/25.2, 25.3, 25.5 [IMAGE AVAILABLE]

142. 4,918,166, Apr. 17, 1990, Particulate hybrid \*\*HIV\*\* antigens; Alan J. Kingsman, et al., 530/350; 424/188.1, 192.1, 208.1; 435/5; 530/395, 403, 806, 812, 824, 826; 536/23.4, 23.72 [IMAGE AVAILABLE]

143. 4,918,075, Apr. 17, 1990, Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents; Robert Zahler, et al., 514/262, 81, 243, 258, 261, 274; 544/244, 254, 264, 265, 276, 277, 280, 313, 314, 317; 546/23, 118; 549/546 [IMAGE AVAILABLE]

144. 4,916,224, Apr. 10, 1990, Dideoxycarbocyclic nucleosides; Robert Vince, et al., 544/254, 264, 265, 267, 276, 277 [IMAGE AVAILABLE]

145. 4,914,135, Apr. 3, 1990, Use of Methylsulfonylmethane to treat parasitic infections; Robert J. Herschler, 514/711; 424/439 [IMAGE AVAILABLE]

146. 4,910,132, Mar. 20, 1990, Virus-free in vitro assay for anti-\*\*HIV\*\* agents; David M. Knight, et al., 435/5, 29, 33, 34, 172.3, 320.1; 436/63; 935/27, 29, 70, 76 [IMAGE AVAILABLE]

147. 4,900,548, Feb. 13, 1990, Use of diethylcarbamazine to enhance antigen-antibody and antigen-host immune cell interactions; Lynn W. Kitchen, 424/207.1, 208.1, 278.1; 436/543; 514/589; 530/389.4 [IMAGE AVAILABLE]

148. 4,894,226, Jan. 16, 1990, Solubilization of proteins for pharmaceutical compositions using polyproline conjugation; Lois Aldwin,

et al., 424/85.2, 85.1, 85.4, 85.6, 179.1 [IMAGE AVAILABLE]

149. 4,880,626, Nov. 14, 1989, Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome; John McMichael, 424/184.1, 115, 198.1, 208.1, 209.1, 234.1, 243.1, 278.1, 282.1; 514/2 [IMAGE AVAILABLE]

150. 4,878,891, Nov. 7, 1989, Method for eradicating infectious biological contaminants in body tissues; Millard M. Judy, et al., 604/5; 128/898; 424/529, 530, 531, 561 [IMAGE AVAILABLE]

151. 4,877,726, Oct. 31, 1989, Method for the detection of acute-phase toxoplasma infection; Yasuhiro Suzuki, et al., 435/7.22; 436/507, 519, 811; 530/350, 403, 822 [IMAGE AVAILABLE]

152. 4,877,610, Oct. 31, 1989, Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms; John McMichael, 424/198.1, 277.1, 282.1, 520; 514/885 [IMAGE AVAILABLE]

153. 4,870,023, Sep. 26, 1989, Recombinant baculovirus occlusion bodies in **\*\*vaccines\*\*** and biological insecticides; Malcolm J. Fraser, et al., 435/235.1, 69.3, 69.7, 172.3, 243, 320.1; 530/350, 820, 826; 536/23.1, 23.4; 930/10, 220; 935/32, 57, 70 [IMAGE AVAILABLE]

154. 4,863,748, Sep. 5, 1989, Dietary products and uses comprising methylsulfonylmethane; Robert J. Herschler, 426/72, 74, 520, 580, 623, 630, 636, 646, 648, 805, 807; 514/711 [IMAGE AVAILABLE]

155. 4,861,720, Aug. 29, 1989, Oncornavirus **\*\*vaccines\*\*** and **\*\*feline\*\*** alpha-type interferon; Neils C. Pedersen, et al., 435/238; 424/207.1 [IMAGE AVAILABLE]

156. 4,859,769, Aug. 22, 1989, Antiviral agents; Karl-Anders Karlsson, et al., 514/25, 53, 613, 625; 536/4.1, 54, 55, 115, 116, 118, 120, 122, 123.13 [IMAGE AVAILABLE]

157. 4,853,326, Aug. 1, 1989, Carbohydrate perturbations of viruses or viral antigens and utilization for diagnostic prophylactic and/or therapeutic applications; Gerard A. Quash, et al., 435/5, 974; 436/507, 518, 543, 548, 812, 820 [IMAGE AVAILABLE]

158. 4,834,976, May 30, 1989, Monoclonal antibodies to pseudomonas aeruginosa flagella; Mae J. Rosok, et al., 424/142.1, 150.1; 435/7.3, 240.27, 804, 875; 436/512, 513, 519, 548, 811; 530/388.15, 388.4; 935/100, 107, 108 [IMAGE AVAILABLE]

159. 4,824,785, Apr. 25, 1989, Canine corona virus **\*\*vaccine\*\***; William M. Acree, et al., 435/237; 424/221.1; 435/235.1, 236, 243, 245 [IMAGE AVAILABLE]

160. 4,812,556, Mar. 14, 1989, Synthetic peptide antigen for the detection of **\*\*HIV\*\***-2 infection; Anders Vahne, et al., 530/324; 930/221, DIG.821 [IMAGE AVAILABLE]

161. 4,806,467, Feb. 21, 1989, Method for the detection of equine infectious anemia and other retrovirus infections using a competitive enzyme-linked immunoabsorbent assay and reagents useful in the same; James P. Porter, et al., 435/5, 7.5, 7.93, 172.1, 172.2; 436/518, 527, 528, 529, 531, 536, 542, 543, 548 [IMAGE AVAILABLE]

162. 4,806,352, Feb. 21, 1989, Immunological lipid emulsion adjuvant; John L. Cantrell, 424/282.1, 184.1, 193.1, 204.1, 216.1, 234.1, 269.1, 274.1, 283.1; 514/21, 885, 937 [IMAGE AVAILABLE]

163. 4,794,168, Dec. 27, 1988, Leukemia-associated virus immunogen, **\*\*vaccine\*\*** and assay; John H. Elder, et al., 530/324, 325, 326, 327; 930/220, 221 [IMAGE AVAILABLE]

164. 4,783,446, Nov. 8, 1988, Method for the treatment of **\*\*AIDS\*\*** virus and other retroviruses; Michael Neushul, 514/54, 885, 934 [IMAGE AVAILABLE]

165. 4,738,922, Apr. 19, 1988, Trans-acting transcriptional factors; William A. Haseltine, et al., 435/69.3, 69.1, 91.41, 172.3, 320.1; 536/23.72, 24.2; 935/32, 34, 39 [IMAGE AVAILABLE]

166. 4,734,362, Mar. 29, 1988, Process for purifying recombinant proteins, and products thereof; Chung-Ho Hung, et al., 435/68.1, 5, 69.1, 69.3; 436/533, 534, 547; 530/412, 826 [IMAGE AVAILABLE]
167. 4,727,027, Feb. 23, 1988, Photochemical decontamination treatment of whole blood or blood components; Gary P. Wieseahn, et al., 435/173.2; 422/24, 28, 29; 424/176.1, 529, 530, 532; 426/234; 435/173.3; 514/2, 6; 530/380, 381, 382, 385, 386, 390.1, 392, 393, 397 [IMAGE AVAILABLE]
168. 4,692,332, Sep. 8, 1987, Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms; John McMichael, 424/198.1, 115, 243.1, 277.1, 282.1, 520; 514/8 [IMAGE AVAILABLE]
169. 4,689,222, Aug. 25, 1987, Methods and materials for alleviation of pain symptoms of malignant neoplasia; John McMichael, 424/198.1, 115, 277.1, 282.1, 520; 514/8, 885 [IMAGE AVAILABLE]
170. 4,652,599, Mar. 24, 1987, Method of continuous production of retroviruses (HTLV-III) from patients with \*\*AIDS\*\* and pre-\*\*AIDS\*\* using permissive cells; Robert C. Gallo, et al., 435/239, 5, 29, 240.2, 240.26, 948; 436/527 [IMAGE AVAILABLE]
171. 4,647,773, Mar. 3, 1987, Method of continuous production of retroviruses (HTLV-III) from patients with \*\*AIDS\*\* and pre-\*\*AIDS\*\*;  
Robert C. Gallo, et al., 435/239; 424/208.1; 435/235.1, 240.26, 948 [IMAGE AVAILABLE]
172. 4,616,039, Oct. 7, 1986, Methylsulfonylmethane in dietary products; Robert J. Herschler, 514/711 [IMAGE AVAILABLE]
173. 4,615,886, Oct. 7, 1986, Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus; Robert H. Purcell, et al., 514/2; 424/529, 530; 514/8 [IMAGE AVAILABLE]
174. 4,567,043, Jan. 28, 1986, Canine corona virus \*\*vaccine\*\*;  
William M. Acree, et al., 424/202.1; 244/900; 424/221.1, 818 [IMAGE AVAILABLE]
175. 4,419,352, Dec. 6, 1983, Pyranoquinolinones and analogs thereof;  
David Cox, et al., 514/291, 232.5, 232.8, 826, 914, 925, 926, 927, 934; 544/126; 546/89, 92 [IMAGE AVAILABLE]
176. 4,303,645, Dec. 1, 1981, Modified living canine parvovirus  
\*\*vaccine\*\*;  
Leland E. Carmichael, et al., 424/233.1, 818; 435/235.1, 237 [IMAGE AVAILABLE]
177. 4,301,281, Nov. 17, 1981, 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid amides; Anthony C. Scotese, et al., 544/80, 117, 279 [IMAGE AVAILABLE]
178. 4,255,568, Mar. 10, 1981, 2H-Pyrimido[4,5-d][1,3]oxazine-2,4(1H)-dione derivatives; Anthony C. Scotese, et al., 544/91 [IMAGE AVAILABLE]
179. 4,236,004, Nov. 25, 1980, 2-Alkylsulphonyl-7,8-dihydro-5-hydroxy-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives; Anthony C. Scotese, et al., 544/279, 117, 255 [IMAGE AVAILABLE]
180. 4,233,446, Nov. 11, 1980, 5-Chloro-7,8-dihydro-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives; Anthony C. Scotese, et al., 544/279; 514/927; 544/117, 255, 317, 323, 329, 332, 334 [IMAGE AVAILABLE]
181. 4,215,216, Jul. 29, 1980, 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives; Anthony C. Scotese, et al., 544/117, 80, 279 [IMAGE AVAILABLE]
182. 4,178,361, Dec. 11, 1979, Sustained release pharmaceutical composition; Arthur I. Cohen, et al., 424/487, 486; 514/454 [IMAGE AVAILABLE]
183. 3,995,027, Nov. 30, 1976, Anti-viral method in animals; Charles Gale, et al., 424/115, 120, 122; 514/23, 894 [IMAGE AVAILAB]

Enter terminal type or "M" for menu -  
Enter terminal type or "M" for menu - VT102

PLEASE ENTER HOST PORT ID:Y

LOGINID:xd18dmm

PASSWORD:\*\*\*\*\*

LOGINID/PASSWORD REJECTED

LOGINID:e yamamoto, janet k/in

E1 3 YAMAMOTO, IZURU/IN  
E2 1 YAMAMOTO, JANET/IN  
E3 3 --> YAMAMOTO, JANET K/IN  
E4 6 YAMAMOTO, JIRO/IN  
E5 1 YAMAMOTO, JOHN R/IN  
E6 1 YAMAMOTO, JOSHIJI/IN  
E7 2 YAMAMOTO, JUICHI/IN  
E8 11 YAMAMOTO, JUN/IN  
E9 2 YAMAMOTO, JUN ICHI/IN  
E10 1 YAMAMOTO, JUNICH/IN  
E11 18 YAMAMOTO, JUNICHI/IN  
E12 10 YAMAMOTO, JUNJI/IN

=> s e2 or e3

1 "YAMAMOTO, JANET"/IN

3 "YAMAMOTO, JANET K"/IN

L1 4 "YAMAMOTO, JANET"/IN OR "YAMAMOTO, JANET K"/IN

=> d 1-4 cit ab

1. 5,275,813, Jan. 4, 1994, Methods and compositions for vaccinating  
against feline immunodeficiency virus; \*\*Janet K. Yamamoto\*\*, et al.,  
424/208.1. 819 [IMAGE AVAILABLE]

US PAT NO: 5,275,813 [IMAGE AVAILABLE]

L1: 1 of 4

#### ABSTRACT:

Compositions derived from a novel viral isolate designated feline immunodeficiency virus (FIV) include the whole virus, proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FIV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses inactivated cell lines expressing FIV antigens, and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

2. 5,118,602, Jun. 2, 1992, Feline T-lymphotropic lentivirus assay;  
Niels C. Pedersen, et al., 435/5. 7.92; 436/518 [IMAGE AVAILABLE]

US PAT NO: 5,118,602 [IMAGE AVAILABLE]

L1: 2 of 4

#### ABSTRACT:

8/335296  
3-95

Compositions derived from a novel viral isolate designated feline T-lymphotropic lentivirus (FTLV) include the whole virus; proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FTLV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

3. 5,037,753, Aug. 6, 1991, Feline t-lymphotropic lentivirus; Niels C. Pedersen, et al., 435/235.1; 424/208.1; 435/5, 948; 530/388.35 [IMAGE AVAILABLE]

US PAT NO: 5,037,753 [IMAGE AVAILABLE] L1: 3 of 4

ABSTRACT:

Compositions derived from a novel viral isolate designated feline T-lymphotropic lentivirus (FTLV) include the whole virus; proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FTLV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

4. 4,861,720, Aug. 29, 1989, Oncornavirus vaccines and feline alpha-type interferon; Neils C. Pedersen, et al., 435/238; 424/207.1 [IMAGE AVAILABLE]

US PAT NO: 4,861,720 [IMAGE AVAILABLE] L1: 4 of 4

ABSTRACT:

Retroviral vaccines are provided comprising incompetent retroviruses containing defective RNA produced by growing viral transformed cells in the presence of interferon. The resulting defective viruses by themselves or in combination with interferon can be used as vaccines for immunizing viral sensitive hosts against infection. A novel feline interferon is produced in culture with cells infected with the defective non-infectious retroviruses.

=> e pedersen, niels d/in

E1	6	PEDERSEN, NIELS C/IN
E2	3	PEDERSEN, NIELS C JR/IN
E3	0 -->	PEDERSEN, NIELS D/IN
E4	1	PEDERSEN, NIELS E/IN
E5	1	PEDERSEN, NIELS H/IN
E6	11	PEDERSEN, NIELS M/IN
E7	3	PEDERSEN, NIELS P/IN
E8	1	PEDERSEN, NIELS PEDER/IN
E9	1	PEDERSEN, NIELS R/IN
E10	11	PEDERSEN, NORMAN E/IN
E11	2	PEDERSEN, OLE K/IN
E12	1	PEDERSEN, OLIVER L/IN

```
=> e per
      dersen, neils d/in
E1      2      PEDERSEN, NARVE S/IN
E2      1      PEDERSEN, NEILS C/IN
E3      0 --> PEDERSEN, NEILS D/IN
E4      5      PEDERSEN, NICHOLAS F/IN
E5      6      PEDERSEN, NIELS C/IN
E6      3      PEDERSEN, NIELS C JR/IN
E7      1      PEDERSEN, NIELS E/IN
E8      1      PEDERSEN, NIELS H/IN
E9      11     PEDERSEN, NIELS M/IN
E10     3      PEDERSEN, NIELS P/IN
E11     1      PEDERSEN, NIELS PEDER/IN
E12     1      PEDERSEN, NIELS R/IN
```

```
=> s e5 or e6
      6 "PEDERSEN, NIELS C"/IN
      3 "PEDERSEN, NIELS C JR"/IN
L2     9 "PEDERSEN, NIELS C"/IN OR "PEDERSEN, NIELS C JR"/IN
```

```
=> d cit 1-9
```

1. 5,291,124, Mar. 1, 1994, Tester for high voltage measuring apparatus; Mark R. Hoffman, et al., 324/72.5, 156; 361/235 [IMAGE AVAILABLE]
2. 5,275,813, Jan. 4, 1994, Methods and compositions for vaccinating against feline immunodeficiency virus; Janet K. Yamamoto, et al., 424/208.1, 819 [IMAGE AVAILABLE]
3. 5,130,642, Jul. 14, 1992, Handing ammeter with removable battery cartridge; Mark R. Hoffman, et al., 324/127, 156 [IMAGE AVAILABLE]
4. 5,118,602, Jun. 2, 1992, Feline T-lymphotropic lentivirus assay; \*\*Niels C. Pedersen\*\*, et al., 435/5, 7.92; 436/518 [IMAGE AVAILABLE]
5. 5,037,753, Aug. 6, 1991, Feline t-lymphotropic lentivirus; \*\*Niels C. Pedersen\*\*, et al., 435/235.1; 424/208.1; 435/5, 948; 530/388.35 [IMAGE AVAILABLE]
6. 5,017,739, May 21, 1991, Jacket for cable connector; Mark R. Hoffman, et al., 174/138F, 92 [IMAGE AVAILABLE]
7. 4,699,785, Oct. 13, 1987, Cell line producing feline leukemia virus; \*\*Niels C. Pedersen\*\*, 424/207.1, 819; 435/235.1, 238, 240.26, 240.31 [IMAGE AVAILABLE]
8. 4,522,810, Jun. 11, 1985, Feline calicivirus vaccine; \*\*Niels C. Pedersen\*\*, 424/216.1, 819; 435/235.1 [IMAGE AVAILABLE]
9. 4,264,587, Apr. 28, 1981, Vaccine for preventing persistent feline leukemia viremia in cats; \*\*Niels C. Pedersen\*\*, et al., 424/207.1, 819; 435/238 [IMAGE AVAILABLE]

```
=> s 424/208.1/ccls
L3      31 424/208.1/CCLS
```

```
=> s 424/207.1/ccls
L4      32 424/207.1/CCLS
```

```
=> s 13 and14
L5      62 L3 OR L4
```



=> s 15 and (fiv or felin@ (5a) immunodeficien? (5a) virus?)

66 FIV

866 FELIN?

1743 IMMUNODEFICIEN?

13332 VIRUS?

26 FELIN? (5A) IMMUNODEFICIEN? (5A) VIRUS?

L6 5 15 AND (FIV OR FELIN? (5A) IMMUNODEFICIEN? (5A) VIRUS?)

=> d cit 1-5

1. 5,275,813, Jan. 4, 1994, Methods and compositions for vaccinating against \*\*feline\*\* \*\*immunodeficiency\*\* \*\*virus\*\*; Janet K. Yamamoto, et al., \*\*424/208.1\*\*, 819 [IMAGE AVAILABLE]

2. 5,256,767, Oct. 26, 1993, Retroviral antigens; Jonas Salk, et al., \*\*424/208.1\*\*, 160.1; 435/236, 238; 530/350, 389.4, 395 [IMAGE AVAILABLE]

3. 5,252,348, Oct. 12, 1993, Artificial viral envelopes; Hans Schreier, et al., 424/450; 264/4.1; 424/196.11, \*\*208.1\*\*, 211.1, 812; 436/829 [IMAGE AVAILABLE]

4. 5,037,753, Aug. 6, 1991, Feline t-lymphotropic lentivirus; Niels C. Pedersen, et al., 435/235.1; \*\*424/208.1\*\*, 435/5, 948; 530/388.35 [IMAGE AVAILABLE]

5. 4,900,548, Feb. 13, 1990, Use of diethylcarbamazine to enhance antigen-antibody and antigen-host immune cell interactions; Lynn W. Kitchen, \*\*424/207.1\*\*, \*\*208.1\*\*, 278.1; 436/543; 514/589; 530/389.4 [IMAGE AVAILABLE]

=> s fiv?

L7 255533 FIV?

=> s feline immunodeficiency virus

699 FELINE

1592 IMMUNODEFICIENCY

10156 VIRUS

L8 18 FELINE IMMUNODEFICIENCY VIRUS  
(FELINE(W)IMMUNODEFICIENCY(W)VIRUS)

=> s 18 and vaccin?

5008 VACCIN?

L9 8 L8 AND VACCIN?

=> d cit 1-8

1. 5,380,830, Jan. 10, 1995, Molecular clones of bovine immunodeficiency-like virus; Matthew A. Gonda, 536/23.1; 435/235.1, 236, 320.1; 536/23.72; 935/6, 9, 19, 32 [IMAGE AVAILABLE]

2. 5,352,665, Oct. 4, 1994, Method of treating disease caused by the infection of virus; Akira Awaya, et al., 514/15; 530/328 [IMAGE AVAILABLE]

3. 5,324,664, Jun. 28, 1994, Herpes virus thymidine kinase-encoding DNA; Jack H. Nunberg, et al., 435/320.1, 69.1, 172.1, 235.1; 530/350; 536/23.1, 23.72, 24.1 [IMAGE AVAILABLE]

4. 5,275,813, Jan. 4, 1994, Methods and compositions for \*\*vaccinating\*\*

against \*\*feline\*\* \*\*immunodeficiency\*\* \*\*virus\*\*; Janet K. Yamamoto, et al., 424/208.1, 819 [IMAGE AVAILABLE]

5. 5,256,767, Oct. 26, 1993, Retroviral antigens; Jonas Salk, et al., 424/208.1, 160.1; 435/236, 238; 530/350, 389.4, 395 [IMAGE AVAILABLE]

6. 5,252,348, Oct. 12, 1993, Artificial viral envelopes; Hans Schreier, et al., 424/450; 264/4.1; 424/196.11, 208.1, 211.1, 812; 436/829 [IMAGE AVAILABLE]

7. 5,118,602, Jun. 2, 1992, Feline T-lymphotropic lentivirus assay; Niels C. Pedersen, et al., 435/5, 7.92; 436/518 [IMAGE AVAILABLE]

8. 5,037,753, Aug. 6, 1991, Feline t-lymphotropic lentivirus; Niels C. Pedersen, et al., 435/235.1; 424/208.1; 435/5, 948; 530/388.35 [IMAGE AVAILABLE]

=> d cit 18 1-18

1. 5,385,899, Jan. 31, 1995, Aminoalkyl-substituted 5,6-dihydro-dibenz[b,e]azepine-6,11-dione-11-oximes; Hanno Wild, et al., 514/217; 540/522 [IMAGE AVAILABLE]

2. 5,380,830, Jan. 10, 1995, Molecular clones of bovine immunodeficiency-like virus; Matthew A. Gonda, 536/23.1; 435/235.1, 236, 320.1; 536/23.72; 935/6, 9, 19, 32 [IMAGE AVAILABLE]

3. 5,364,931, Nov. 15, 1994, Phosphonate-containing pseudopeptides of the hydroxyethylamine and norstatin type; Dieter Habich, et al., 530/331; 546/22, 23; 548/111 [IMAGE AVAILABLE]

4. 5,356,886, Oct. 18, 1994, Antiviral phosphono-alken derivatives of purines; Michael R. Harnden, et al., 514/81; 544/244; 549/221; 556/405, 482; 558/177 [IMAGE AVAILABLE]

5. 5,352,665, Oct. 4, 1994, Method of treating disease caused by the infection of virus; Akira Awaya, et al., 514/15; 530/328 [IMAGE AVAILABLE]

6. 5,324,664, Jun. 28, 1994, Herpes virus thymidine kinase-encoding DNA; Jack H. Nunberg, et al., 435/320.1, 69.1, 172.1, 172.3, 235.1; 530/350; 536/23.1, 23.72, 24.1 [IMAGE AVAILABLE]

7. 5,275,813, Jan. 4, 1994, Methods and compositions for vaccinating against \*\*feline\*\* \*\*immunodeficiency\*\* \*\*virus\*\*; Janet K. Yamamoto, et al., 424/208.1, 819 [IMAGE AVAILABLE]

8. 5,256,767, Oct. 26, 1993, Retroviral antigens; Jonas Salk, et al., 424/208.1, 160.1; 435/236, 238; 530/350, 389.4, 395 [IMAGE AVAILABLE]

9. 5,252,348, Oct. 12, 1993, Artificial viral envelopes; Hans Schreier, et al., 424/450; 264/4.1; 424/196.11, 208.1, 211.1, 812; 436/829 [IMAGE AVAILABLE]

10. 5,219,725, Jun. 15, 1993, Monoclonal antibodies to feline-T-lymphotropic lentivirus; Thomas P. O'Connor, et al., 435/5; 436/548; 530/388.35 [IMAGE AVAILABLE]

11. 5,177,083, Jan. 5, 1993, Drugs effective against retroviruses; Darryl C. Rideout, et al., 530/296, 632, 639, 664, 666 [IMAGE AVAILABLE]

12. 5,177,014, Jan. 5, 1993, Monoclonal antibodies to feline-T-lymphotropic lentivirus; Thomas P. O'Connor, et al., 435/188. 5, 7.92; 530/388.5, 391.3 [IMAGE AVAILABLE]

13. 5,162,538, Nov. 10, 1992, Antiviral new peptides; Klaus-Peter Voges, et al., 546/336, 337 [IMAGE AVAILABLE]

14. 5,147,865, Sep. 15, 1992, Phosphonopyrrolidine- and piperidine-containing pseudopeptides of the statin type, a process for their preparation and their use as medicaments against retroviruses; Dieter Habich, et al., 514/91, 7, 79, 82, 85, 89, 90, 92, 93, 94; 544/129, 337; 546/22; 548/412 [IMAGE AVAILABLE]

15. 5,145,951, Sep. 8, 1992, Peptides retroviral protease inhibitors comprising 2-amino-2-methylpropionic acid; Klaus-Peter Voges, et al., 530/330, 331 [IMAGE AVAILABLE]

16. 5,126,238, Jun. 30, 1992, Hollow fiber cell propagation system and method; Timothy C. Gebhard, et al., 435/3; 204/409; 422/82.04; 435/240.1, 240.242, 284, 289, 291, 807 [IMAGE AVAILABLE]

17. 5,118,602, Jun. 2, 1992, Feline T-lymphotropic lentivirus assay; Niels C. Pedersen, et al., 435/5, 7.92; 436/518 [IMAGE AVAILABLE]

18. 5,037,753, Aug. 6, 1991, Feline t-lymphotropic lentivirus; Niels C. Pedersen, et al., 435/235.1; 424/208.1; 435/5, 948; 530/388.35 [IMAGE AVAILABLE]

=> s 18 and felin?

866 FELIN?

L10 18 L8 AND FELIN?

=> d his

(FILE 'USPAT' ENTERED AT 15:31:20 ON 22 MAR 95)

E YAMAMOTO, JANET K/IN

L1 4 S E2 OR E3

E PEDERSEN, NIELS D/IN

E PEDERSEN, NEILS D/IN

L2 9 S E5 OR E6

L3 31 S 424/208.1/CCLS

L4 32 S 424/207.1/CCLS

L5 62 S L3 OR L4

L6 5 S L5 AND (FIV OR FELIN? (5A) IMMUNODEFICIEN? (5A) VIRUS?)

L7 255533 S FIV?

L8 18 S FELINE IMMUNODEFICIENCY VIRUS

L9 8 S L8 AND VACCIN?

L10 18 S L8 AND FELIN?

=> s 15 and felin?

866 FELIN?

L11 33 L5 AND FELIN?

=> s 111 and AIDS

60501 AIDS

L12 14 L11 AND AIDS

=> d cit ab

1. 5,352,449, Oct. 4, 1994, Vaccine comprising recombinant \*\*feline\*\* leukemia antigen and saponin adjuvant; Gerald A. Beltz, et al., 424/187.1, \*\*207.1\*\*, 278.1, 819; 514/8, 12 [IMAGE AVAILABLE]

US PAT NO: 5,352,449 [IMAGE AVAILABLE]

L12: 1 of 14

ABSTRACT:

The invention relates to antigenic preparations useful for inducing the production of antibodies in a cat which will bind to epitopes on \*\*feline\*\* leukemia virus. Also disclosed are immunogenic compositions and methods for immunizing a cat to enable the production of antibodies to \*\*feline\*\* leukemia virus.

=> d cit ab 2-14

2. 5,275,813, Jan. 4, 1994, Methods and compositions for vaccinating against \*\*feline\*\* immunodeficiency virus; Janet K. Yamamoto, et al., \*\*424/208.1\*\*, 819 [IMAGE AVAILABLE]

US PAT NO: 5,275,813 [IMAGE AVAILABLE]

L12: 2 of 14

ABSTRACT:

Compositions derived from a novel viral isolate designated \*\*feline\*\* immunodeficiency virus (FIV) include the whole virus, proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FIV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses inactivated cell lines expressing FIV antigens, and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

3. 5,256,767, Oct. 26, 1993, Retroviral antigens; Jonas Salk, et al., \*\*424/208.1\*\*, 160.1; 435/236, 238; 530/350, 389.4, 395 [IMAGE AVAILABLE]

US PAT NO: 5,256,767 [IMAGE AVAILABLE]

L12: 3 of 14

ABSTRACT:

The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.

4. 5,252,348, Oct. 12, 1993, Artificial viral envelopes; Hans Schreier, et al., 424/450; 264/4.1; 424/196.11, \*\*208.1\*\*, 211.1, 812; 436/829 [IMAGE AVAILABLE]

US PAT NO: 5,252,348 [IMAGE AVAILABLE]

L12: 4 of 14

ABSTRACT:

The production of artificial viral envelopes by a novel double-detergent dialysis technique is disclosed. Specifically exemplified is the production of HIV-1 and RSV viral envelopes. The resulting artificial viral envelopes are essentially identical to the natural virus with regard to characteristics which are relevant to immunogenicity.

5. 5,174,993, Dec. 29, 1992, Recombinant avipox virus and immunological use thereof; Enzo Paolletti, 424/199.1, \*\*207.1\*\*, 210.1, 214.1, 222.1, 224.1, 231.1, 232.1; 435/235.1, 320.1; 935/32, 57, 65 [IMAGE AVAILABLE]

US PAT NO: 5,174,993 [IMAGE AVAILABLE]

L12: 5 of 14

ABSTRACT:

The present invention provides a method for inducing an immunological response in a vertebrate to a pathogen by inoculating the vertebrate with a synthetic recombinant avipox virus modified by the presence, in a non-essential region of the avipox genome, of DNA from any source which codes for and expresses an antigen of the pathogen. The present invention further provides a synthetic recombinant avipox virus modified by the insertion therein of DNA from any source, and particularly from a non-avipox source, into a non-essential region of the avipox genome.

6. 5,037,753, Aug. 6, 1991, \*\*Feline\*\* t-lymphotropic lentivirus; Niels C. Pedersen, et al., 435/235.1; \*\*424/208.1\*\*; 435/5, 948; 530/388.35 [IMAGE AVAILABLE]

US PAT NO: 5,037,753 [IMAGE AVAILABLE]

L12: 6 of 14

ABSTRACT:

Compositions derived from a novel viral isolate designated \*\*feline\*\* T-lymphototropic lentivirus (FTLV) include the whole virus; proteins, polypeptides and, polynucleotide sequences derived from the virus; and antibodies to antigenic sites on the virus. These compositions are useful in a variety of techniques for the detection of and vaccination against FTLV. Detection methods disclosed include immunoassays for both the virus and antibodies to the virus, and the use of polynucleotide probes to detect the viral genome. Vaccines include both wholly and partially inactivated viruses and subunit vaccines. Whole, live virus is also useful as a model system for predicting the behavior of human immunodeficiency virus (HIV).

7. 4,983,387, Jan. 8, 1991, HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for \*\*AIDS\*\* virus; Allen Goldstein, et al., 424/188.1, 196.11, \*\*208.1\*\*; 530/324, 325, 326, 345, 388.23, 389.2, 403, 806, 807; 930/221 [IMAGE AVAILABLE]

US PAT NO: 4,983,387 [IMAGE AVAILABLE]

L12: 7 of 14

ABSTRACT:

Vaccines effective in the inhibition of infection caused by the family of retroviruses, HTLV-III, Human T-Cell Leukemia Virus, LAV, Lymphadenopathy-associated virus, ARV-2, \*\*AIDS\*\*-Related Virus, (\*\*AIDS\*\* and \*\*AIDS\*\*-Related Complex) have been developed from an antisera prepared against thymosin .alpha..sub.1 (T.alpha..sub.1), a thymic hormone, as well as from antisera to synthetic peptide fragments of T.alpha..sub.1 and antisera to synthetic peptide inclusive of amino acid positions 92-109 of the p17 gag core protein of HTLV-III, LAV and

ARV-2. In this 18 amino acid primary sequence that is a 44 to 50% homology between the gag protein and T.alpha..sub.1. Immunoqlobulin (IgG)- enriched preparations of the T.alpha..sub.1 antisera have enhanced activity in blocking viral replication. A diagnostic test capable of directly detecting the presence of HTLV-III, LAV, ARV-2 and related retroviruses associated with \*\*AIDS\*\* and ARC is also described.

8. 4,965,069, Oct. 23, 1990, Oxidized viruses or viral antigens and utilization for diagnostic prophylactic and/or therapeutic applications; Gerard A. Quash, et al., \*\*424/208.1\*\*, 204.1, 209.1, 211.1, 212.1, 215.1, 216.1, 219.1, 225.1, 230.1, 231.1; 435/238 [IMAGE AVAILABLE]

US PAT NO: 4,965,069 [IMAGE AVAILABLE] L12: 8 of 14

ABSTRACT:

Novel and improved methods for diagnosis, prognosis, prophylaxis and therapy of viral infections are described. The novel methods employ a virus, viral antigen or fragment thereof in which "perturbation" of an oligosaccharide moiety renders the virus, viral antigen or fragment thereof more specifically recognizable or reactive with neutralizing antibody. As described, "perturbation" of an oligosaccharide moiety encompasses a variety of modifications such as one that (1) alters the chemical or physical structure of a carbohydrate residue that is naturally present; (2) that removes, wholly or in part, a carbohydrate residue; and/or (3) that prevents or alters addition of a carbohydrate residue. A variety of different methods for oligosaccharide "perturbation" are also described. In particular, the carbohydrate residue is altered by an oxidizing agent.

9. 4,918,166, Apr. 17, 1990, Particulate hybrid HIV antigens; Alan J. Kinsman, et al., 530/350; 424/188.1, 192.1, \*\*208.1\*\*, 435/5; 530/395, 403, 806, 812, 824, 826; 536/23.4, 23.72 [IMAGE AVAILABLE]

US PAT NO: 4,918,166 [IMAGE AVAILABLE] L12: 9 of 14

ABSTRACT:

Fusion proteins comprise a77 first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the YTA gene of the yeast retrotransposon Ty. The second amino acid sequence is an HIV antigen. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.

10. 4,900,548, Feb. 13, 1990, Use of diethylcarbamazine to enhance antigen-antibody and antigen-host immune cell interactions; Lynn W. Kitchen, \*\*424/207.1\*\*, \*\*208.1\*\*, 278.1; 436/543; 514/589; 530/389.4 [IMAGE AVAILABLE]

US PAT NO: 4,900,548 [IMAGE AVAILABLE] L12: 10 of 14

ABSTRACT:

This invention relates to the use of diethylcarbamazine (DEC), its analogs, homologs, and pharmaceutically acceptable salts thereof as an antiviral agent. This invention further relates to the use of DEC in in vivo diagnosis to increase antibodies to a particular disease; to the use of DEC in in vitro serologic assays to increase efficacy; and to the use of DEC as a vaccine adjuvant.

11. 4,880,626, Nov. 14, 1988, Immunotherapeutic methods and compositions

for the treatment of diseases of viral origin, including acquired immune deficiency syndrome; John McMichael, 424/184.1, 115, 198.1, \*\*208.1\*\*, 209.1, 234.1, 243.1, 278.1, 282.1: 514/2 [IMAGE AVAILABLE]

US PAT NO: 4.880.626 [IMAGE AVAILABLE]

L12: 11 of 14

ABSTRACT:

Methods and compositions useful for treating acquired immune deficiency syndrome by once daily administration of substances characteristic of acquired immune deficiency syndrome-afflicted cell (such as human chorionic gonadotropin), and effective fragments and derivatives thereof, in a pharmaceutically effective amount less than the lowest amount necessary to provoke a humoral immune response, as exemplified by the existence of a negative wheal upon subcutaneous administration. Illustrative of such methods and compositions is the administration of a composition including human chorionic gonadotropin (HCG), a lysate of Staphylococcus aureus, influenza virus vaccine, and fractionated HIV virus, including peptide T.

12. 4.861.720. Aug. 29, 1989. Oncornavirus vaccines and \*\*feline\*\* alpha-type interferon: Neils C. Pedersen, et al., 435/239: \*\*424/207.1\*\* [IMAGE AVAILABLE]

US PAT NO: 4.861.720 [IMAGE AVAILABLE]

L12: 12 of 14

ABSTRACT:

Retroviral vaccines are provided comprising incompetent retroviruses containing defective RNA produced by growing viral transformed cells in the presence of interferon. The resulting defective viruses by themselves or in combination with interferon can be used as vaccines for immunizing viral sensitive hosts against infection. A novel \*\*feline\*\* interferon is produced in culture with cells infected with the defective non-infectious retroviruses.

13. 4.822.606. Apr. 18, 1989. Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences: Ralph D. Snyderman, et al., 424/188.1, 187.1, 196.11, \*\*207.1\*\*: 530/324, 326, 345, 350, 403: 930/10, 221, DIG.811, DIG.821 [IMAGE AVAILABLE]

US PAT NO: 4.822.606 [IMAGE AVAILABLE]

L12: 13 of 14

ABSTRACT:

Novel peptides having immunosuppressive or immunoregulatory activity are disclosed.

14. 4.647.773. Mar. 3, 1987. Method of continuous production of retroviruses (HTLV-III) from patients with \*\*AIDS\*\* and pre-\*\*\*AIDS\*\*: Robert C. Gallo, et al., 435/239: \*\*424/208.1\*\*: 435/235.1, 240.26, 948 [IMAGE AVAILABLE]

US PAT NO: 4.647.773 [IMAGE AVAILABLE]

L12: 14 of 14

ABSTRACT:

A cell system is disclosed for the reproducible detection and isolation of human T-lymphotropic retroviruses (HTLV-family) with cytopathic effects (HTLV-III) from patients with the acquired immune deficiency syndrome (\*\*AIDS\*\*), pre-\*\*\*AIDS\*\* and in healthy carriers. One neoplastic aneuploid T-cell line derived from an adult with lymphoid leukemia, and termed HT, was susceptible to infection with the new variants of HTLV, which are transformed and providing T-cell populations which are highly

susceptible and permissive from HTLV-III. and convenience for large scale production, isolation and biological detection of the virus.

=> d fd

US PAT NO:	5.352.449 [IMAGE AVAILABLE]	L12: 1 of 14
DATE FILED:	Apr. 14. 1992	

=> d fd 1-14

US PAT NO:	5.352.449 [IMAGE AVAILABLE]	L12: 1 of 14
DATE FILED:	Apr. 14. 1992	

US PAT NO:	5.275.813 [IMAGE AVAILABLE]	L12: 2 of 14
DATE FILED:	Jul. 31. 1991	

US PAT NO:	5.256.767 [IMAGE AVAILABLE]	L12: 3 of 14
DATE FILED:	Nov. 10. 1992	

US PAT NO:	5.252.348 [IMAGE AVAILABLE]	L12: 4 of 14
DATE FILED:	Jul. 30. 1992	

US PAT NO:	5.174.993 [IMAGE AVAILABLE]	L12: 5 of 14
DATE FILED:	Jun. 14. 1990	

US PAT NO:	5.037.753 [IMAGE AVAILABLE]	L12: 6 of 14
DATE FILED:	Nov. 16. 1990	

US PAT NO:	4.983.387 [IMAGE AVAILABLE]	L12: 7 of 14
DATE FILED:	Jan. 23. 1989	

US PAT NO:	4.965.069 [IMAGE AVAILABLE]	L12: 8 of 14
DATE FILED:	May 20. 1987	

US PAT NO:	4.918.166 [IMAGE AVAILABLE]	L12: 9 of 14
DATE FILED:	Oct. 26. 1987	

US PAT NO:	4.900.548 [IMAGE AVAILABLE]	L12: 10 of 14
DATE FILED:	Nov. 13. 1987	

US PAT NO:	4.880.626 [IMAGE AVAILABLE]	L12: 11 of 14
DATE FILED:	Aug. 17. 1987	

US PAT NO:	4.861.720 [IMAGE AVAILABLE]	L12: 12 of 14
DATE FILED:	Jul. 3. 1986	

US PAT NO:	4.822.606 [IMAGE AVAILABLE]	L12: 13 of 14
DATE FILED:	Apr. 7. 1986	

US PAT NO:	4.647.773 [IMAGE AVAILABLE]	L12: 14 of 14
DATE FILED:	Apr. 23. 1984	

=> s1111 and adjuvant?

25011 ADJUVANT?

L13 31 L11 AND ADJUVANT?

=> s 113 and vaccin?

50008 VACCIN?

L14 31 L13 AND VACCIN?



=> s 114 and FIV  
66 FIV  
L15 1 114 AND FIV

=> d cit fd

1. 5,275,813. Jan. 4, 1994. Methods and compositions for **\*\*vaccinating\*\***  
against **\*\*feline\*\*** immunodeficiency virus: Janet K. Yamamoto, et al.,  
**\*\*474/200,188, 819 IMAGE AVAILABLE\*\***

US PAT NO: 5,275,813 [IMAGE AVAILABLE] L15: 1 of 1  
DATE FILED: Jan. 23, 1994

=> logoff  
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF  
LOGOFF? (Y)/N/HOLD:v  
U.S. Patent &